Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects
Schizophrenia is associated with immune system dysfunction, including aberrant cytokine levels. We performed a meta-analysis of these associations, considering effects of clinical status and antipsychotic treatment following an acute illness exacerbation. We identified articles by searching PubMed,...
Saved in:
| Published in | Biological psychiatry (1969) Vol. 70; no. 7; pp. 663 - 671 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Elsevier Inc
01.10.2011
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0006-3223 1873-2402 1873-2402 |
| DOI | 10.1016/j.biopsych.2011.04.013 |
Cover
Loading…
| Abstract | Schizophrenia is associated with immune system dysfunction, including aberrant cytokine levels. We performed a meta-analysis of these associations, considering effects of clinical status and antipsychotic treatment following an acute illness exacerbation.
We identified articles by searching PubMed, PsychInfo, and Institute for Scientific Information and the reference lists of identified studies.
Forty studies met the inclusion criteria. Effect sizes were similar for studies of acutely relapsed inpatients (AR) and first-episode psychosis (FEP). Interleukin (IL)-1β, IL-6, and transforming growth factor-β (TGF-β) appeared to be state markers, as they were increased in AR and FEP (
p < .001 for each) and normalized with antipsychotic treatment (
p < .001,
p = .008, and
p = .005, respectively). In contrast, IL-12, interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), and soluble IL-2 receptor (sIL-2R) appeared to be trait markers, as levels remained elevated in acute exacerbations and following antipsychotic treatment. There was no difference in IL-6 levels between stable medicated outpatients and control subjects (
p = .69). In the cerebrospinal fluid, IL-1β was significantly decreased in schizophrenia versus controls (
p = .01).
Similar effect sizes in AR and FEP suggest that the association between cytokine abnormalities and acute exacerbations of schizophrenia is independent of antipsychotic medications. While some cytokines (IL-1β, IL-6, and TGF-β) may be state markers for acute exacerbations, others (IL-12, IFN-γ, TNF-α, and sIL-2R) may be trait markers. Although these results could provide the basis for future hypothesis testing, most studies did not control for potential confounding factors such as body mass index and smoking. |
|---|---|
| AbstractList | Background Schizophrenia is associated with immune system dysfunction, including aberrant cytokine levels. We performed a meta-analysis of these associations, considering effects of clinical status and antipsychotic treatment following an acute illness exacerbation. Methods We identified articles by searching PubMed, PsychInfo, and Institute for Scientific Information and the reference lists of identified studies. Results Forty studies met the inclusion criteria. Effect sizes were similar for studies of acutely relapsed inpatients (AR) and first-episode psychosis (FEP). Interleukin (IL)-1β, IL-6, and transforming growth factor-β (TGF-β) appeared to be state markers, as they were increased in AR and FEP ( p < .001 for each) and normalized with antipsychotic treatment ( p < .001, p = .008, and p = .005, respectively). In contrast, IL-12, interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), and soluble IL-2 receptor (sIL-2R) appeared to be trait markers, as levels remained elevated in acute exacerbations and following antipsychotic treatment. There was no difference in IL-6 levels between stable medicated outpatients and control subjects ( p = .69). In the cerebrospinal fluid, IL-1β was significantly decreased in schizophrenia versus controls ( p = .01). Conclusions Similar effect sizes in AR and FEP suggest that the association between cytokine abnormalities and acute exacerbations of schizophrenia is independent of antipsychotic medications. While some cytokines (IL-1β, IL-6, and TGF-β) may be state markers for acute exacerbations, others (IL-12, IFN-γ, TNF-α, and sIL-2R) may be trait markers. Although these results could provide the basis for future hypothesis testing, most studies did not control for potential confounding factors such as body mass index and smoking. Schizophrenia is associated with immune system dysfunction, including aberrant cytokine levels. We performed a meta-analysis of these associations, considering effects of clinical status and antipsychotic treatment following an acute illness exacerbation. We identified articles by searching PubMed, PsychInfo, and Institute for Scientific Information and the reference lists of identified studies. Forty studies met the inclusion criteria. Effect sizes were similar for studies of acutely relapsed inpatients (AR) and first-episode psychosis (FEP). Interleukin (IL)-1β, IL-6, and transforming growth factor-β (TGF-β) appeared to be state markers, as they were increased in AR and FEP (p < .001 for each) and normalized with antipsychotic treatment (p < .001, p = .008, and p = .005, respectively). In contrast, IL-12, interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), and soluble IL-2 receptor (sIL-2R) appeared to be trait markers, as levels remained elevated in acute exacerbations and following antipsychotic treatment. There was no difference in IL-6 levels between stable medicated outpatients and control subjects (p = .69). In the cerebrospinal fluid, IL-1β was significantly decreased in schizophrenia versus controls (p = .01). Similar effect sizes in AR and FEP suggest that the association between cytokine abnormalities and acute exacerbations of schizophrenia is independent of antipsychotic medications. While some cytokines (IL-1β, IL-6, and TGF-β) may be state markers for acute exacerbations, others (IL-12, IFN-γ, TNF-α, and sIL-2R) may be trait markers. Although these results could provide the basis for future hypothesis testing, most studies did not control for potential confounding factors such as body mass index and smoking. Schizophrenia is associated with immune system dysfunction, including aberrant cytokine levels. We performed a meta-analysis of these associations, considering effects of clinical status and antipsychotic treatment following an acute illness exacerbation.BACKGROUNDSchizophrenia is associated with immune system dysfunction, including aberrant cytokine levels. We performed a meta-analysis of these associations, considering effects of clinical status and antipsychotic treatment following an acute illness exacerbation.We identified articles by searching PubMed, PsychInfo, and Institute for Scientific Information and the reference lists of identified studies.METHODSWe identified articles by searching PubMed, PsychInfo, and Institute for Scientific Information and the reference lists of identified studies.Forty studies met the inclusion criteria. Effect sizes were similar for studies of acutely relapsed inpatients (AR) and first-episode psychosis (FEP). Interleukin (IL)-1β, IL-6, and transforming growth factor-β (TGF-β) appeared to be state markers, as they were increased in AR and FEP (p < .001 for each) and normalized with antipsychotic treatment (p < .001, p = .008, and p = .005, respectively). In contrast, IL-12, interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), and soluble IL-2 receptor (sIL-2R) appeared to be trait markers, as levels remained elevated in acute exacerbations and following antipsychotic treatment. There was no difference in IL-6 levels between stable medicated outpatients and control subjects (p = .69). In the cerebrospinal fluid, IL-1β was significantly decreased in schizophrenia versus controls (p = .01).RESULTSForty studies met the inclusion criteria. Effect sizes were similar for studies of acutely relapsed inpatients (AR) and first-episode psychosis (FEP). Interleukin (IL)-1β, IL-6, and transforming growth factor-β (TGF-β) appeared to be state markers, as they were increased in AR and FEP (p < .001 for each) and normalized with antipsychotic treatment (p < .001, p = .008, and p = .005, respectively). In contrast, IL-12, interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), and soluble IL-2 receptor (sIL-2R) appeared to be trait markers, as levels remained elevated in acute exacerbations and following antipsychotic treatment. There was no difference in IL-6 levels between stable medicated outpatients and control subjects (p = .69). In the cerebrospinal fluid, IL-1β was significantly decreased in schizophrenia versus controls (p = .01).Similar effect sizes in AR and FEP suggest that the association between cytokine abnormalities and acute exacerbations of schizophrenia is independent of antipsychotic medications. While some cytokines (IL-1β, IL-6, and TGF-β) may be state markers for acute exacerbations, others (IL-12, IFN-γ, TNF-α, and sIL-2R) may be trait markers. Although these results could provide the basis for future hypothesis testing, most studies did not control for potential confounding factors such as body mass index and smoking.CONCLUSIONSSimilar effect sizes in AR and FEP suggest that the association between cytokine abnormalities and acute exacerbations of schizophrenia is independent of antipsychotic medications. While some cytokines (IL-1β, IL-6, and TGF-β) may be state markers for acute exacerbations, others (IL-12, IFN-γ, TNF-α, and sIL-2R) may be trait markers. Although these results could provide the basis for future hypothesis testing, most studies did not control for potential confounding factors such as body mass index and smoking. Schizophrenia is associated with immune system dysfunction, including aberrant cytokine levels. We performed a meta-analysis of these associations, considering effects of clinical status and antipsychotic treatment following an acute illness exacerbation. We identified articles by searching PubMed, PsychInfo, and Institute for Scientific Information and the reference lists of identified studies. Forty studies met the inclusion criteria. Effect sizes were similar for studies of acutely relapsed inpatients (AR) and first-episode psychosis (FEP). Interleukin (IL)-1β, IL-6, and transforming growth factor-β (TGF-β) appeared to be state markers, as they were increased in AR and FEP ( p < .001 for each) and normalized with antipsychotic treatment ( p < .001, p = .008, and p = .005, respectively). In contrast, IL-12, interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), and soluble IL-2 receptor (sIL-2R) appeared to be trait markers, as levels remained elevated in acute exacerbations and following antipsychotic treatment. There was no difference in IL-6 levels between stable medicated outpatients and control subjects ( p = .69). In the cerebrospinal fluid, IL-1β was significantly decreased in schizophrenia versus controls ( p = .01). Similar effect sizes in AR and FEP suggest that the association between cytokine abnormalities and acute exacerbations of schizophrenia is independent of antipsychotic medications. While some cytokines (IL-1β, IL-6, and TGF-β) may be state markers for acute exacerbations, others (IL-12, IFN-γ, TNF-α, and sIL-2R) may be trait markers. Although these results could provide the basis for future hypothesis testing, most studies did not control for potential confounding factors such as body mass index and smoking. |
| Author | Miller, Brian J. Seabolt, Wesley Buckley, Peter Mellor, Andrew Kirkpatrick, Brian |
| Author_xml | – sequence: 1 givenname: Brian J. surname: Miller fullname: Miller, Brian J. email: brmiller@georgiahealth.edu organization: Department of Psychiatry and Health Behavior, Georgia Health Sciences University, Augusta, Georgia – sequence: 2 givenname: Peter surname: Buckley fullname: Buckley, Peter organization: School of Medicine, Georgia Health Sciences University, Augusta, Georgia – sequence: 3 givenname: Wesley surname: Seabolt fullname: Seabolt, Wesley organization: Department of Psychiatry and Health Behavior, Georgia Health Sciences University, Augusta, Georgia – sequence: 4 givenname: Andrew surname: Mellor fullname: Mellor, Andrew organization: Immunotherapy Center, Georgia Health Sciences University, Augusta, Georgia – sequence: 5 givenname: Brian surname: Kirkpatrick fullname: Kirkpatrick, Brian organization: Department of Psychiatry and Behavioral Science, Texas A&M University and Scott and White Hospital, Temple, Texas |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/21641581$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNUk1vEzEQtVARTQt_odobp009XmfXQagiikpBKuIQOFte75g43djBdiptfz1OkyDogXKyRn4fo3nvjJw475CQC6BjoFBfrsat9Zs46OWYUYAx5WMK1QsyAtFUJeOUnZARpbQuK8aqU3IW4yqPDWPwipwyqDlMBIyI-oJJlTOn-iHaWHhTzIfk76zDYtYnDCpZ72JhXbHQS_vgN8uAzqp3xby3zmrVF4uk0jYWynXFzCX7uJNPVhfXxqBO8TV5aVQf8c3hPSffP15_m38qb7_efJ7Pbktd8zqVRvO8lUI9UXxaVx3tmDFKCMF4ZVoKRlCEBlnTCmBGTQwqzttWi6nWHBRU5-Rqr7vZtmvsNLoUVC83wa5VGKRXVv794-xS_vD3ktMGKkqzwNuDQPA_txiTXNuose-VQ7-NUkzZlDcgREZe_Gn12-N41gx4vwfo4GMMaKS26fGU2dn2EqjcpShX8pii3KUoKZc5xUyvn9CPDs8SP-yJmA99bzHIqC06jZ0NOQvZefu8xNUTCX1I-g4HjCu_DbksUYKMTFK52HVsVzEASjnlk38L_M8GvwDWdefp |
| CitedBy_id | crossref_primary_10_1016_j_schres_2015_08_027 crossref_primary_10_1177_0269881112467089 crossref_primary_10_1177_00048674211013086 crossref_primary_10_1016_j_bbih_2020_100192 crossref_primary_10_1016_j_psychres_2022_114588 crossref_primary_10_1016_S2215_0366_15_00309_0 crossref_primary_10_1016_j_bbi_2022_07_006 crossref_primary_10_1016_j_pnpbp_2012_10_022 crossref_primary_10_1016_j_pnpbp_2023_110834 crossref_primary_10_1016_j_bbi_2023_10_012 crossref_primary_10_1016_j_bbi_2014_06_013 crossref_primary_10_23736_S2724_5276_16_04642_9 crossref_primary_10_1016_j_ejphar_2018_12_003 crossref_primary_10_1016_j_pnpbp_2016_09_004 crossref_primary_10_1038_s41398_019_0570_y crossref_primary_10_1016_j_bbi_2020_04_021 crossref_primary_10_3389_fnmol_2022_1028963 crossref_primary_10_1186_s13041_014_0085_7 crossref_primary_10_1016_j_schres_2022_01_049 crossref_primary_10_1007_s00213_016_4413_8 crossref_primary_10_3389_fpsyt_2017_00238 crossref_primary_10_3389_fimmu_2025_1533335 crossref_primary_10_3109_08039488_2014_984755 crossref_primary_10_3109_15622975_2013_830774 crossref_primary_10_1111_prd_12452 crossref_primary_10_1007_s00787_020_01568_7 crossref_primary_10_1016_j_schres_2013_04_021 crossref_primary_10_3389_fpsyt_2021_536257 crossref_primary_10_1016_j_pnpbp_2023_110823 crossref_primary_10_1016_j_schres_2018_06_033 crossref_primary_10_1016_j_jpsychires_2025_01_036 crossref_primary_10_1080_08039488_2021_1919201 crossref_primary_10_3389_fpsyt_2021_665682 crossref_primary_10_1016_j_jpsychires_2024_07_029 crossref_primary_10_1016_j_schres_2013_04_028 crossref_primary_10_1016_j_schres_2018_06_039 crossref_primary_10_3389_fnmol_2021_733012 crossref_primary_10_3389_fpsyt_2017_00221 crossref_primary_10_3390_vaccines11020208 crossref_primary_10_1016_j_neulet_2020_135491 crossref_primary_10_3390_jcm12020683 crossref_primary_10_1016_j_bbi_2020_05_055 crossref_primary_10_1371_journal_pone_0174073 crossref_primary_10_1016_j_pnpbp_2012_02_001 crossref_primary_10_1016_j_dcn_2014_07_001 crossref_primary_10_1016_j_jpsychires_2018_08_017 crossref_primary_10_3928_00485713_20180405_01 crossref_primary_10_1016_j_schres_2015_07_006 crossref_primary_10_47183_mes_2025_27_1_56_63 crossref_primary_10_1016_j_amp_2018_08_017 crossref_primary_10_1111_cen3_12531 crossref_primary_10_3109_01677063_2014_882918 crossref_primary_10_1097_YIC_0000000000000303 crossref_primary_10_1159_000511552 crossref_primary_10_1021_cn5003368 crossref_primary_10_1016_j_pharmthera_2018_06_012 crossref_primary_10_1016_j_pneurobio_2018_09_002 crossref_primary_10_1111_eip_12859 crossref_primary_10_3389_fpsyt_2022_880568 crossref_primary_10_1017_S0033291714000166 crossref_primary_10_3389_fimmu_2022_907851 crossref_primary_10_1016_j_schres_2016_03_039 crossref_primary_10_1080_14789450_2016_1252262 crossref_primary_10_1016_j_ajp_2016_06_018 crossref_primary_10_1016_j_pnpbp_2014_06_012 crossref_primary_10_30773_pi_2022_0173 crossref_primary_10_3389_fpsyt_2022_1003034 crossref_primary_10_1007_s11064_017_2341_6 crossref_primary_10_1016_j_pneurobio_2020_101967 crossref_primary_10_1038_mp_2016_90 crossref_primary_10_1016_j_biopsych_2013_09_019 crossref_primary_10_1016_j_euroneuro_2015_08_004 crossref_primary_10_1016_j_schres_2016_11_004 crossref_primary_10_18621_eurj_586551 crossref_primary_10_1016_j_bbi_2014_05_012 crossref_primary_10_1016_j_psychres_2018_08_002 crossref_primary_10_1016_j_bbih_2022_100551 crossref_primary_10_1016_j_pnpbp_2022_110511 crossref_primary_10_1111_jdv_14303 crossref_primary_10_1016_j_jpsychires_2022_02_029 crossref_primary_10_1016_j_pnpbp_2022_110510 crossref_primary_10_1016_j_jid_2017_06_020 crossref_primary_10_1016_j_schres_2013_05_018 crossref_primary_10_3389_fimmu_2021_667179 crossref_primary_10_1038_npp_2016_66 crossref_primary_10_3389_fimmu_2018_02596 crossref_primary_10_1254_fpj_142_276 crossref_primary_10_1523_JNEUROSCI_3481_13_2014 crossref_primary_10_1016_j_cyto_2012_06_266 crossref_primary_10_1093_ijnp_pyu042 crossref_primary_10_1016_j_rpsmen_2017_07_002 crossref_primary_10_1016_j_brainres_2015_02_043 crossref_primary_10_1016_j_schres_2015_09_030 crossref_primary_10_1038_s41537_024_00466_0 crossref_primary_10_1016_j_psyneuen_2016_05_015 crossref_primary_10_1111_jog_15821 crossref_primary_10_1080_08039488_2016_1230649 crossref_primary_10_1093_ijnp_pyu037 crossref_primary_10_1016_j_eurpsy_2016_05_010 crossref_primary_10_17816_CP11067 crossref_primary_10_1016_j_ibneur_2022_08_009 crossref_primary_10_1016_j_pnpbp_2017_03_020 crossref_primary_10_1111_eip_12889 crossref_primary_10_1016_j_psychres_2016_07_059 crossref_primary_10_1016_j_jpsychires_2016_12_001 crossref_primary_10_1159_000432400 crossref_primary_10_1016_j_bbi_2015_02_021 crossref_primary_10_1038_s41598_021_94007_9 crossref_primary_10_1371_journal_pone_0140052 crossref_primary_10_3389_fpsyt_2019_00363 crossref_primary_10_1016_j_euroneuro_2016_01_009 crossref_primary_10_1093_schbul_sby160 crossref_primary_10_1038_s41380_019_0434_0 crossref_primary_10_3389_fpsyt_2024_1463974 crossref_primary_10_1192_apt_bp_113_011452 crossref_primary_10_3109_08039488_2014_986761 crossref_primary_10_3390_biology11010061 crossref_primary_10_1189_jlb_0212100 crossref_primary_10_1038_tp_2014_46 crossref_primary_10_17116_jnevro202412411142 crossref_primary_10_1186_s12888_024_06163_7 crossref_primary_10_1080_13651501_2016_1197274 crossref_primary_10_1111_appy_12207 crossref_primary_10_17116_jnevro202512502135 crossref_primary_10_1016_j_psychres_2017_11_086 crossref_primary_10_1111_cbdd_12843 crossref_primary_10_1080_14737175_2021_1994857 crossref_primary_10_1186_s12888_024_06141_z crossref_primary_10_31363_2313_7053_2023_699 crossref_primary_10_1038_s41598_024_65181_3 crossref_primary_10_3390_jcm12041577 crossref_primary_10_1016_j_schres_2024_12_010 crossref_primary_10_1016_j_psyneuen_2015_09_010 crossref_primary_10_1016_j_jpsychires_2019_02_023 crossref_primary_10_1007_s10597_017_0203_y crossref_primary_10_1155_2019_4576842 crossref_primary_10_17116_jnevro201911903192 crossref_primary_10_1080_08039488_2016_1216595 crossref_primary_10_1186_s12888_023_05081_4 crossref_primary_10_4306_pi_2017_14_5_703 crossref_primary_10_1007_s00406_024_01885_x crossref_primary_10_1016_j_bbi_2018_11_318 crossref_primary_10_1002_glia_22998 crossref_primary_10_1016_j_bbi_2018_11_315 crossref_primary_10_1016_j_nbd_2013_07_003 crossref_primary_10_2174_0118715249271548231115071021 crossref_primary_10_30773_pi_2019_04_14 crossref_primary_10_2174_1570159X22666231128101725 crossref_primary_10_1016_j_bbi_2023_12_035 crossref_primary_10_1002_hup_2652 crossref_primary_10_31363_2313_7053_2020_4_65_72 crossref_primary_10_1016_j_bbi_2017_11_020 crossref_primary_10_1016_j_bbih_2022_100518 crossref_primary_10_1016_j_jpsychires_2024_05_013 crossref_primary_10_3389_fpsyt_2019_00103 crossref_primary_10_1016_j_pnpbp_2017_03_006 crossref_primary_10_1002_wps_20026 crossref_primary_10_1016_j_neuroscience_2017_01_033 crossref_primary_10_3390_biomedicines9070734 crossref_primary_10_1007_s00406_016_0749_7 crossref_primary_10_1186_1742_2094_10_43 crossref_primary_10_1016_j_jpsychires_2013_05_018 crossref_primary_10_1016_j_msard_2022_103522 crossref_primary_10_3389_fgene_2022_813510 crossref_primary_10_1016_j_bbi_2014_12_005 crossref_primary_10_1016_j_bbi_2017_10_003 crossref_primary_10_1016_j_psyneuen_2016_02_011 crossref_primary_10_1016_j_schres_2020_09_007 crossref_primary_10_1159_000379751 crossref_primary_10_4274_forbes_galenos_2022_48658 crossref_primary_10_1016_j_schres_2018_12_017 crossref_primary_10_1038_s41380_024_02743_x crossref_primary_10_1093_schbul_sby113 crossref_primary_10_1111_pim_12157 crossref_primary_10_1016_j_bbi_2014_04_008 crossref_primary_10_1016_j_jpsychires_2019_01_006 crossref_primary_10_1038_s41537_020_0098_4 crossref_primary_10_1017_S0033291717000022 crossref_primary_10_1016_j_pnpbp_2024_110959 crossref_primary_10_1038_s41537_021_00161_4 crossref_primary_10_3389_fpsyt_2014_00136 crossref_primary_10_3389_fpsyt_2014_00137 crossref_primary_10_1159_000510886 crossref_primary_10_1016_j_psychres_2016_08_055 crossref_primary_10_1186_s12974_020_01890_6 crossref_primary_10_3389_fgene_2021_647246 crossref_primary_10_1016_j_psyneuen_2013_12_005 crossref_primary_10_1007_s11011_014_9630_4 crossref_primary_10_9758_cpn_2013_11_3_144 crossref_primary_10_1016_j_biopsych_2018_02_1171 crossref_primary_10_1016_j_bbi_2019_06_006 crossref_primary_10_1097_WNF_0000000000000181 crossref_primary_10_1097_YCO_0b013e328363b4da crossref_primary_10_1111_pcn_12906 crossref_primary_10_1016_j_euroneuro_2018_12_011 crossref_primary_10_1093_schbul_sby125 crossref_primary_10_1016_j_psyneuen_2020_105071 crossref_primary_10_3389_fncel_2014_00370 crossref_primary_10_1111_cpr_13295 crossref_primary_10_1016_j_bbi_2020_06_017 crossref_primary_10_1016_j_psychres_2014_04_049 crossref_primary_10_1126_sciadv_aau8317 crossref_primary_10_1016_j_biopsych_2013_09_037 crossref_primary_10_1038_s41598_022_15617_5 crossref_primary_10_31363_2313_7053_2023_893 crossref_primary_10_1016_j_physbeh_2014_02_032 crossref_primary_10_1111_eip_12456 crossref_primary_10_1017_S0033291725000467 crossref_primary_10_1016_j_biopsych_2023_11_029 crossref_primary_10_1111_eip_12457 crossref_primary_10_1016_j_psychres_2014_11_007 crossref_primary_10_1111_eip_12459 crossref_primary_10_1016_j_psychres_2017_02_030 crossref_primary_10_1097_01_XME_0000508433_27202_4e crossref_primary_10_4103_ipj_ipj_38_21 crossref_primary_10_1186_s12888_024_06287_w crossref_primary_10_1016_j_euroneuro_2018_12_008 crossref_primary_10_1007_s40473_021_00235_8 crossref_primary_10_1007_s00406_023_01677_9 crossref_primary_10_1016_j_eurpsy_2016_01_635 crossref_primary_10_1186_s12888_024_06032_3 crossref_primary_10_1017_S204579601400033X crossref_primary_10_1016_j_psyneuen_2018_06_021 crossref_primary_10_1016_j_schres_2013_07_029 crossref_primary_10_1007_s11126_020_09731_8 crossref_primary_10_1159_000441521 crossref_primary_10_3390_ijms231911324 crossref_primary_10_3389_fcimb_2024_1423739 crossref_primary_10_3390_app122110915 crossref_primary_10_1007_s12038_018_9751_8 crossref_primary_10_1093_schbul_sbv078 crossref_primary_10_3390_ph14060514 crossref_primary_10_1016_j_cpnec_2023_100192 crossref_primary_10_1111_cen3_12389 crossref_primary_10_1038_s41380_018_0220_4 crossref_primary_10_1016_j_psyneuen_2021_105350 crossref_primary_10_1084_jem_20180794 crossref_primary_10_1007_s10597_016_0063_x crossref_primary_10_1111_jnc_16258 crossref_primary_10_1016_j_bbi_2023_03_025 crossref_primary_10_1016_j_neubiorev_2014_02_001 crossref_primary_10_3389_fpsyt_2017_00203 crossref_primary_10_3390_brainsci13050836 crossref_primary_10_3390_ijms18040733 crossref_primary_10_1016_j_pnpbp_2023_110875 crossref_primary_10_1186_s12888_016_1039_7 crossref_primary_10_1016_j_schres_2021_03_022 crossref_primary_10_1111_j_2153_9588_2012_01095_x crossref_primary_10_3390_biom14060688 crossref_primary_10_1007_s11033_013_2662_8 crossref_primary_10_1016_j_bbi_2020_07_037 crossref_primary_10_1038_s41398_023_02570_8 crossref_primary_10_1016_S2215_0366_15_00115_7 crossref_primary_10_1016_j_ajp_2017_01_026 crossref_primary_10_1134_S1819712420330016 crossref_primary_10_1093_cercor_bhaa236 crossref_primary_10_3389_fpsyt_2019_00996 crossref_primary_10_1016_j_pmip_2023_100106 crossref_primary_10_3390_ijms21176106 crossref_primary_10_1176_appi_focus_20170046 crossref_primary_10_1016_j_cyto_2021_155582 crossref_primary_10_3390_biomedicines12020457 crossref_primary_10_1007_s11011_019_00466_5 crossref_primary_10_1017_S0033291719001454 crossref_primary_10_9758_cpn_2013_11_3_107 crossref_primary_10_1016_j_schres_2016_03_018 crossref_primary_10_5213_inj_1632614_307 crossref_primary_10_3390_ph13120457 crossref_primary_10_1016_j_bbi_2020_07_043 crossref_primary_10_3892_etm_2019_7285 crossref_primary_10_1016_j_bbi_2019_06_043 crossref_primary_10_1017_S0033291718003690 crossref_primary_10_1016_j_pharmthera_2018_05_005 crossref_primary_10_1016_j_schres_2011_11_013 crossref_primary_10_3371_CSRP_KIMI_031513 crossref_primary_10_1016_j_aimed_2014_12_007 crossref_primary_10_1038_tp_2016_40 crossref_primary_10_1590_2237_6089_2015_0007 crossref_primary_10_3389_fpsyt_2018_00753 crossref_primary_10_1111_sji_12620 crossref_primary_10_1111_nyas_12764 crossref_primary_10_1038_npjschz_2016_31 crossref_primary_10_3390_brainsci12091154 crossref_primary_10_1007_s10552_016_0826_2 crossref_primary_10_1021_acs_analchem_3c01447 crossref_primary_10_1016_j_ijpsycho_2017_02_001 crossref_primary_10_3389_fpsyt_2024_1358578 crossref_primary_10_1016_j_bbi_2016_09_008 crossref_primary_10_1016_j_lpm_2015_10_016 crossref_primary_10_1093_schbul_sbv028 crossref_primary_10_1002_wps_20672 crossref_primary_10_3389_fpsyt_2023_1231750 crossref_primary_10_1016_j_schres_2021_02_008 crossref_primary_10_17116_jnevro2021121061132 crossref_primary_10_1007_s12264_016_0094_x crossref_primary_10_1007_s11920_015_0574_0 crossref_primary_10_1016_j_psyneuen_2016_03_002 crossref_primary_10_1038_srep23791 crossref_primary_10_3390_biom13081188 crossref_primary_10_1111_pcn_12089 crossref_primary_10_1016_j_bbi_2023_03_015 crossref_primary_10_1016_j_psychres_2014_10_007 crossref_primary_10_1176_appi_focus_20160006 crossref_primary_10_1016_j_euroneuro_2023_06_003 crossref_primary_10_1016_j_schres_2013_08_036 crossref_primary_10_1016_j_ajp_2019_03_012 crossref_primary_10_1590_S0101_60832012005000003 crossref_primary_10_3389_fpsyt_2022_943869 crossref_primary_10_1016_j_schres_2018_07_019 crossref_primary_10_1016_j_jad_2018_11_011 crossref_primary_10_1186_s40360_017_0171_4 crossref_primary_10_1192_bjo_2020_76 crossref_primary_10_3109_15622975_2014_922699 crossref_primary_10_1007_s12035_024_04401_3 crossref_primary_10_1002_dvdy_24612 crossref_primary_10_1038_s41398_021_01645_8 crossref_primary_10_1111_eip_12267 crossref_primary_10_1017_S0954579416000717 crossref_primary_10_1016_j_bbih_2024_100756 crossref_primary_10_3389_fendo_2020_00195 crossref_primary_10_1007_s12264_016_0022_0 crossref_primary_10_1016_j_bbi_2012_06_010 crossref_primary_10_1176_appi_focus_18309 crossref_primary_10_1038_s41398_022_02291_4 crossref_primary_10_1016_j_psychres_2014_06_039 crossref_primary_10_1016_j_schres_2015_12_001 crossref_primary_10_1016_j_cca_2017_08_011 crossref_primary_10_1016_j_lfs_2015_02_010 crossref_primary_10_1016_j_psychres_2020_113380 crossref_primary_10_1523_JNEUROSCI_1116_18_2018 crossref_primary_10_1016_j_stem_2013_10_011 crossref_primary_10_1016_j_jpsychires_2017_03_018 crossref_primary_10_1186_s41038_018_0134_z crossref_primary_10_1016_j_schres_2014_02_005 crossref_primary_10_1186_s12888_023_05250_5 crossref_primary_10_1016_j_schres_2019_04_021 crossref_primary_10_1016_j_schres_2023_05_005 crossref_primary_10_1038_tp_2016_148 crossref_primary_10_1089_gtmb_2015_0168 crossref_primary_10_1093_schbul_sbab149 crossref_primary_10_1111_acps_12211 crossref_primary_10_1111_acps_12453 crossref_primary_10_1017_neu_2020_12 crossref_primary_10_13005_bpj_1343 crossref_primary_10_1016_j_schres_2016_06_031 crossref_primary_10_1093_schbul_sbu049 crossref_primary_10_1038_s41598_024_76013_9 crossref_primary_10_1371_journal_pone_0125112 crossref_primary_10_1038_nrneurol_2014_187 crossref_primary_10_17116_jnevro202112105284 crossref_primary_10_1016_j_bbi_2023_06_023 crossref_primary_10_1016_j_schres_2018_11_035 crossref_primary_10_1016_j_psychres_2013_12_035 crossref_primary_10_1186_s13063_023_07789_w crossref_primary_10_1016_j_cyto_2017_04_004 crossref_primary_10_3390_life12121972 crossref_primary_10_1016_j_bbi_2014_09_009 crossref_primary_10_1016_j_jpsychires_2016_09_017 crossref_primary_10_1186_1742_2094_10_142 crossref_primary_10_1186_s12888_022_04312_4 crossref_primary_10_1016_j_jpsychires_2023_01_042 crossref_primary_10_1007_s40263_014_0146_6 crossref_primary_10_1016_j_bbi_2020_08_028 crossref_primary_10_1016_S2215_0366_17_30293_6 crossref_primary_10_1016_j_bbi_2023_06_009 crossref_primary_10_20307_nps_2024_30_2_93 crossref_primary_10_3390_ijms24032215 crossref_primary_10_1016_j_bbi_2018_03_013 crossref_primary_10_1016_j_psychres_2016_09_032 crossref_primary_10_15789_1563_0625_AOI_2806 crossref_primary_10_1007_s00406_023_01650_6 crossref_primary_10_3389_fnut_2022_943998 crossref_primary_10_1111_1346_8138_15290 crossref_primary_10_1159_000512082 crossref_primary_10_1176_appi_focus_10_2_115 crossref_primary_10_1371_journal_pone_0257946 crossref_primary_10_5937_mp74_40330 crossref_primary_10_1007_s00213_015_4044_5 crossref_primary_10_1007_s12035_019_01737_z crossref_primary_10_1016_j_intimp_2019_106093 crossref_primary_10_1111_acps_12423 crossref_primary_10_1016_j_bbi_2018_03_022 crossref_primary_10_3389_fpsyt_2022_977538 crossref_primary_10_5812_ans_142694 crossref_primary_10_1007_s00406_023_01587_w crossref_primary_10_1017_neu_2019_14 crossref_primary_10_1016_j_schres_2016_05_010 crossref_primary_10_1186_s12974_018_1096_6 crossref_primary_10_1016_j_plefa_2016_03_010 crossref_primary_10_3371_CSRP_SSSO_071717 crossref_primary_10_1080_15622975_2020_1775890 crossref_primary_10_1007_s12264_017_0103_8 crossref_primary_10_1016_j_schres_2014_03_005 crossref_primary_10_1017_S0033291724000199 crossref_primary_10_1007_s00278_019_0366_9 crossref_primary_10_1093_schbul_sbt141 crossref_primary_10_1186_1742_2094_9_206 crossref_primary_10_1038_npp_2016_116 crossref_primary_10_1016_j_euroneuro_2023_04_003 crossref_primary_10_1038_s41398_018_0158_y crossref_primary_10_1007_s00018_016_2175_4 crossref_primary_10_1016_j_schres_2015_11_002 crossref_primary_10_1016_j_comppsych_2019_01_003 crossref_primary_10_1007_s11011_025_01548_3 crossref_primary_10_3390_jpm12071137 crossref_primary_10_3892_etm_2021_10320 crossref_primary_10_1093_schbul_sbab106 crossref_primary_10_1111_pcn_13476 crossref_primary_10_2147_NDT_S396168 crossref_primary_10_1002_ajmg_b_32457 crossref_primary_10_1016_j_psychres_2016_11_017 crossref_primary_10_1016_j_schres_2014_04_041 crossref_primary_10_1016_j_biopsych_2014_07_013 crossref_primary_10_1016_j_neubiorev_2018_07_001 crossref_primary_10_1038_tp_2017_134 crossref_primary_10_1016_j_burns_2018_05_007 crossref_primary_10_1176_appi_ajp_2015_15010019 crossref_primary_10_1016_j_jneuroim_2014_09_019 crossref_primary_10_1016_j_schres_2014_03_024 crossref_primary_10_1038_s41537_020_00133_0 crossref_primary_10_1016_j_rpsm_2023_04_002 crossref_primary_10_1016_j_schres_2014_03_020 crossref_primary_10_3389_fpsyt_2022_966439 crossref_primary_10_9758_cpn_2014_12_1_8 crossref_primary_10_1016_j_jneuroim_2020_577165 crossref_primary_10_2147_NDT_S470127 crossref_primary_10_1016_j_pnpbp_2020_110130 crossref_primary_10_1038_s41386_018_0038_4 crossref_primary_10_1016_j_psyneuen_2021_105200 crossref_primary_10_1093_ijnp_pyy062 crossref_primary_10_1093_schbul_sbt120 crossref_primary_10_1016_j_bionps_2019_100006 crossref_primary_10_1002_ajmg_b_32691 crossref_primary_10_1007_s00702_022_02566_6 crossref_primary_10_1097_YCT_0000000000000303 crossref_primary_10_1093_schbul_sbaa041 crossref_primary_10_3390_ijms20236050 crossref_primary_10_18097_PBMC20186402201 crossref_primary_10_1016_j_physbeh_2016_10_021 crossref_primary_10_1093_schizbullopen_sgab017 crossref_primary_10_1016_j_scog_2015_10_004 crossref_primary_10_1016_j_jpsychires_2012_03_019 crossref_primary_10_1186_s12888_025_06512_0 crossref_primary_10_3389_fpsyt_2018_00007 crossref_primary_10_3390_ijms23031731 crossref_primary_10_1016_j_psyneuen_2018_11_028 crossref_primary_10_1016_j_schres_2014_03_035 crossref_primary_10_3389_fnmol_2016_00016 crossref_primary_10_3390_jcm11216352 crossref_primary_10_1007_s00213_013_3383_3 crossref_primary_10_3892_etm_2015_2604 crossref_primary_10_1080_24750573_2017_1380920 crossref_primary_10_1007_s12640_018_9987_y crossref_primary_10_1016_j_brainres_2019_146463 crossref_primary_10_1016_j_bbi_2023_05_005 crossref_primary_10_1038_s41537_023_00398_1 crossref_primary_10_1016_j_bbi_2023_05_001 crossref_primary_10_1016_j_psychres_2017_03_038 crossref_primary_10_4155_fsoa_2017_0009 crossref_primary_10_1155_2014_493505 crossref_primary_10_1016_j_pscychresns_2015_06_006 crossref_primary_10_1016_j_schres_2013_11_040 crossref_primary_10_1038_s41398_022_02197_1 crossref_primary_10_1038_s41598_023_49206_x crossref_primary_10_1007_s12264_022_00970_2 crossref_primary_10_1016_j_jpsychires_2021_11_020 crossref_primary_10_3389_fpsyt_2017_00083 crossref_primary_10_1007_s11126_021_09954_3 crossref_primary_10_3892_etm_2017_4075 crossref_primary_10_1016_j_bbi_2016_12_010 crossref_primary_10_1038_mp_2014_59 crossref_primary_10_1016_j_jpsychires_2023_03_030 crossref_primary_10_2217_fnl_2020_0026 crossref_primary_10_1186_s12888_020_02683_0 crossref_primary_10_1016_S2215_0366_16_00021_3 crossref_primary_10_1007_s00701_024_06101_2 crossref_primary_10_3233_HAB_180344 crossref_primary_10_1089_cap_2015_0220 crossref_primary_10_3389_fnins_2018_00296 crossref_primary_10_3390_ijerph13070625 crossref_primary_10_1016_j_pscychresns_2020_111219 crossref_primary_10_3389_fnhum_2016_00406 crossref_primary_10_1016_j_bbi_2012_08_016 crossref_primary_10_1111_pcn_13670 crossref_primary_10_1016_j_bbih_2022_100584 crossref_primary_10_1111_acps_13140 crossref_primary_10_1111_add_15160 crossref_primary_10_1007_s40336_015_0140_0 crossref_primary_10_1080_08039488_2019_1688389 crossref_primary_10_1016_j_psyneuen_2018_10_009 crossref_primary_10_1001_jamapsychiatry_2024_0796 crossref_primary_10_1016_j_jid_2024_01_005 crossref_primary_10_1017_neu_2022_38 crossref_primary_10_1093_schizbullopen_sgab002 crossref_primary_10_1038_npp_2016_143 crossref_primary_10_1080_13546805_2018_1440201 crossref_primary_10_1093_schbul_sbr178 crossref_primary_10_1016_j_bpsgos_2022_01_006 crossref_primary_10_1038_s41398_021_01499_0 crossref_primary_10_1111_imm_12795 crossref_primary_10_9758_cpn_2021_19_1_112 crossref_primary_10_1007_s00127_014_0887_z crossref_primary_10_1007_s00406_014_0533_5 crossref_primary_10_1016_j_bbi_2022_10_007 crossref_primary_10_3109_08039488_2015_1122079 crossref_primary_10_1016_j_bbi_2017_06_006 crossref_primary_10_1016_j_psychres_2018_12_012 crossref_primary_10_1016_j_bbih_2023_100636 crossref_primary_10_1016_j_bbi_2012_08_005 crossref_primary_10_1016_j_schres_2013_10_019 crossref_primary_10_31887_DCNS_2017_19_1_nmueller crossref_primary_10_3390_ijms21239182 crossref_primary_10_1111_acps_13351 crossref_primary_10_1002_phar_2689 crossref_primary_10_1016_j_pbb_2020_172981 crossref_primary_10_5937_jomb0_28108 crossref_primary_10_1016_j_jpsychires_2021_11_002 crossref_primary_10_1016_j_schres_2013_10_011 crossref_primary_10_1016_j_schres_2016_07_006 crossref_primary_10_1177_0972753120929565 crossref_primary_10_1371_journal_pone_0258199 crossref_primary_10_1016_j_ajp_2021_102605 crossref_primary_10_1016_j_euroneuro_2023_03_014 crossref_primary_10_1007_s12640_019_00112_z crossref_primary_10_1038_mp_2014_66 crossref_primary_10_1177_0004867420983454 crossref_primary_10_1016_j_schres_2013_10_009 crossref_primary_10_1016_j_schres_2012_01_040 crossref_primary_10_1038_s41380_022_01582_y crossref_primary_10_1186_s13229_016_0110_z crossref_primary_10_1016_j_psyneuen_2020_104645 crossref_primary_10_30773_pi_2018_12_19_1 crossref_primary_10_1038_s41380_020_00952_8 crossref_primary_10_1038_s41398_022_02305_1 crossref_primary_10_1016_j_schres_2019_03_012 crossref_primary_10_1016_j_neubiorev_2016_02_017 crossref_primary_10_1038_s41398_021_01311_z crossref_primary_10_1016_j_pnpbp_2012_11_008 crossref_primary_10_1093_schbul_sbac098 crossref_primary_10_1134_S102279542001010X crossref_primary_10_1016_j_pnpbp_2012_11_007 crossref_primary_10_1016_j_bbi_2020_10_026 crossref_primary_10_17116_jnevro201811812172 crossref_primary_10_1097_MD_0000000000019694 crossref_primary_10_2174_1871523019999201110192029 crossref_primary_10_1097_HRP_0000000000000322 crossref_primary_10_3923_ijp_2015_596_603 crossref_primary_10_1021_acschemneuro_8b00205 crossref_primary_10_1111_pcn_12794 crossref_primary_10_1002_jcp_27330 crossref_primary_10_1016_j_bbi_2022_07_162 crossref_primary_10_1016_j_msard_2016_02_004 crossref_primary_10_1038_s41398_023_02442_1 crossref_primary_10_3390_cells9030577 crossref_primary_10_1002_ajmg_b_32622 crossref_primary_10_1016_j_bbi_2015_03_002 crossref_primary_10_1016_j_neures_2016_01_006 crossref_primary_10_3389_fpsyt_2024_1356975 crossref_primary_10_1016_j_schres_2020_05_036 crossref_primary_10_1016_j_schres_2014_05_019 crossref_primary_10_1016_j_schres_2019_05_018 crossref_primary_10_1016_j_comppsych_2017_01_008 crossref_primary_10_1038_npp_2016_198 crossref_primary_10_3389_fpsyt_2022_925757 crossref_primary_10_1017_S0033291717000745 crossref_primary_10_1016_j_jpsychires_2014_04_017 crossref_primary_10_1016_j_jneuroim_2020_577344 crossref_primary_10_1016_j_psychres_2012_05_036 crossref_primary_10_1016_j_bbi_2023_08_001 crossref_primary_10_1016_j_jpsychires_2015_12_013 crossref_primary_10_1016_j_neubiorev_2019_12_011 crossref_primary_10_1177_0269881118788830 crossref_primary_10_1016_j_schres_2019_05_028 crossref_primary_10_1039_C4MB00157E crossref_primary_10_1097_YIC_0000000000000241 crossref_primary_10_1038_s41380_019_0428_y crossref_primary_10_1097_YIC_0000000000000481 crossref_primary_10_1007_s12035_022_03199_2 crossref_primary_10_1007_s00210_023_02437_1 crossref_primary_10_1016_j_schres_2020_05_026 crossref_primary_10_1016_j_psychres_2016_10_061 crossref_primary_10_1016_j_schres_2016_09_026 crossref_primary_10_1016_j_eurpsy_2017_09_007 crossref_primary_10_1007_s00406_021_01334_z crossref_primary_10_1007_s11306_022_01909_4 crossref_primary_10_1136_eb_2014_101996 crossref_primary_10_1177_0004867419864438 crossref_primary_10_1097_HRP_0000000000000101 crossref_primary_10_1080_15622975_2018_1459048 crossref_primary_10_1016_j_schres_2017_01_016 crossref_primary_10_1016_j_bbr_2021_113229 crossref_primary_10_1016_j_heliyon_2020_e03990 crossref_primary_10_1016_j_neuropharm_2015_09_019 crossref_primary_10_1097_HRP_0000000000000109 crossref_primary_10_1038_tp_2014_8 crossref_primary_10_1051_medsci_20153101014 crossref_primary_10_5665_sleep_5216 crossref_primary_10_1111_acps_12217 crossref_primary_10_21307_ane_2018_008 crossref_primary_10_1016_j_rpsmen_2018_03_003 crossref_primary_10_1097_01_XME_0000513069_03258_07 crossref_primary_10_1016_j_bbi_2021_04_002 crossref_primary_10_1016_j_pnpbp_2018_07_015 crossref_primary_10_1016_j_nbd_2016_12_019 crossref_primary_10_1016_j_neubiorev_2021_09_023 crossref_primary_10_3390_genes12020237 crossref_primary_10_1038_s41398_022_01968_0 crossref_primary_10_1042_CS20211106 crossref_primary_10_1016_j_psychres_2024_115871 crossref_primary_10_1016_j_scitotenv_2020_142008 crossref_primary_10_3389_fpsyt_2018_00082 crossref_primary_10_1007_s11064_021_03348_4 crossref_primary_10_1016_j_jad_2016_06_016 crossref_primary_10_1016_j_schres_2017_01_026 crossref_primary_10_1186_1741_7015_11_200 crossref_primary_10_3390_jcm12124012 crossref_primary_10_1093_ije_dyz201 crossref_primary_10_3390_jpm13091382 crossref_primary_10_1038_mp_2016_50 crossref_primary_10_1177_15500594241294035 crossref_primary_10_1016_j_pnpbp_2012_12_001 crossref_primary_10_1124_pharmrev_122_000618 crossref_primary_10_1038_mp_2017_43 crossref_primary_10_1038_s41398_020_01079_8 crossref_primary_10_1038_tp_2013_5 crossref_primary_10_1016_j_jpsychires_2015_11_002 crossref_primary_10_1007_s40501_017_0114_0 crossref_primary_10_3390_ijms26010385 crossref_primary_10_1038_s41537_024_00469_x crossref_primary_10_1016_j_neuroscience_2015_06_028 crossref_primary_10_1176_appi_focus_20200015 crossref_primary_10_1146_annurev_clinpsy_081219_112621 crossref_primary_10_1016_j_bbih_2020_100070 crossref_primary_10_1016_j_schres_2020_12_020 crossref_primary_10_1016_j_schres_2017_04_015 crossref_primary_10_1016_j_schres_2023_02_027 crossref_primary_10_1016_j_bbr_2016_11_049 crossref_primary_10_1038_nrn_2017_125 crossref_primary_10_3390_biology14040336 crossref_primary_10_1002_npr2_12261 crossref_primary_10_1016_j_neubiorev_2022_104608 crossref_primary_10_1016_j_jpsychires_2015_03_015 crossref_primary_10_1016_j_pnpbp_2024_111092 crossref_primary_10_1016_j_psyneuen_2015_02_007 crossref_primary_10_3389_fnins_2015_00172 crossref_primary_10_1016_j_psychres_2017_07_002 crossref_primary_10_5567_pharmacologia_2015_438_453 crossref_primary_10_1016_j_schres_2023_02_020 crossref_primary_10_1016_S2215_0366_19_30290_1 crossref_primary_10_1152_ajpregu_00087_2015 crossref_primary_10_1007_s00406_022_01519_0 crossref_primary_10_1016_j_ajp_2023_103636 crossref_primary_10_1016_j_pnpbp_2018_05_005 crossref_primary_10_1080_15622975_2019_1583371 crossref_primary_10_1038_mp_2015_96 crossref_primary_10_3390_cells11182788 crossref_primary_10_1016_j_ijdevneu_2017_01_009 crossref_primary_10_1002_14651858_CD012116_pub2 crossref_primary_10_1016_j_psyneuen_2012_04_001 crossref_primary_10_1016_j_psychres_2017_09_071 crossref_primary_10_1016_j_taap_2019_114643 crossref_primary_10_1016_j_psychres_2018_02_002 crossref_primary_10_3390_cells12010054 crossref_primary_10_1016_j_pnpbp_2012_09_016 crossref_primary_10_3389_fnins_2017_00490 crossref_primary_10_1002_glia_24629 crossref_primary_10_1016_j_bcp_2021_114532 crossref_primary_10_1016_j_euroneuro_2020_03_014 crossref_primary_10_3389_fmed_2021_757655 crossref_primary_10_9758_cpn_2012_10_2_61 crossref_primary_10_1016_j_biopsych_2013_10_003 crossref_primary_10_1016_j_psychres_2018_12_097 crossref_primary_10_1038_mp_2016_3 crossref_primary_10_1016_j_bbi_2016_02_005 crossref_primary_10_1016_j_biopsych_2013_03_018 crossref_primary_10_1016_j_jpsychores_2015_06_011 crossref_primary_10_3109_13651501_2016_1149195 crossref_primary_10_1186_s12888_023_05136_6 crossref_primary_10_33920_med_01_2502_13 crossref_primary_10_3389_fncel_2022_1046692 crossref_primary_10_1111_exd_14979 crossref_primary_10_1016_j_npbr_2019_05_002 crossref_primary_10_1017_thg_2014_70 crossref_primary_10_1186_s12888_023_05234_5 crossref_primary_10_1186_s12974_017_0842_5 crossref_primary_10_1002_wps_20117 crossref_primary_10_3389_fpsyt_2019_00892 crossref_primary_10_1080_00325481_2021_2006514 crossref_primary_10_3390_bs11060086 crossref_primary_10_1371_journal_pmed_1003284 crossref_primary_10_3390_jcm10173849 crossref_primary_10_1016_j_schres_2014_06_025 crossref_primary_10_1186_s12944_020_01337_0 crossref_primary_10_1007_s12640_016_9637_1 crossref_primary_10_1136_bmjopen_2022_067944 crossref_primary_10_1186_s12888_023_04896_5 crossref_primary_10_3390_ph14050446 crossref_primary_10_1007_s00406_017_0847_1 crossref_primary_10_1016_j_lfs_2020_117442 crossref_primary_10_1016_j_bbi_2018_05_002 crossref_primary_10_1016_j_schres_2020_05_044 crossref_primary_10_1093_jnen_nly103 crossref_primary_10_1007_s00406_021_01237_z crossref_primary_10_1111_exd_13401 crossref_primary_10_1016_j_bbi_2018_05_006 crossref_primary_10_1016_j_schres_2015_01_026 crossref_primary_10_1038_s41598_024_73937_0 crossref_primary_10_1016_j_pnpbp_2013_04_001 crossref_primary_10_1038_s41398_021_01764_2 crossref_primary_10_1038_srep10793 crossref_primary_10_1016_j_neubiorev_2015_05_014 crossref_primary_10_4236_health_2019_115040 crossref_primary_10_1007_s12035_015_9489_3 crossref_primary_10_1016_j_neulet_2011_10_042 crossref_primary_10_1186_s13073_018_0576_8 crossref_primary_10_1016_j_neubiorev_2021_03_004 crossref_primary_10_1016_j_neuroscience_2015_05_018 crossref_primary_10_2174_1570159X21666230322145049 crossref_primary_10_3389_fpsyt_2020_00121 crossref_primary_10_1016_j_pneurobio_2014_08_002 crossref_primary_10_1038_mp_2017_89 crossref_primary_10_1146_annurev_psych_010416_044208 crossref_primary_10_1016_j_bbi_2013_03_001 crossref_primary_10_4137_IJTR_S25915 crossref_primary_10_1016_j_euroneuro_2020_04_002 crossref_primary_10_3389_fnins_2015_00372 crossref_primary_10_1002_14651858_CD012116 crossref_primary_10_1038_s41380_019_0566_2 crossref_primary_10_1016_j_bbi_2016_03_005 crossref_primary_10_1080_14737175_2016_1256206 crossref_primary_10_1093_schbul_sby038 crossref_primary_10_1016_j_jneuroim_2017_11_008 crossref_primary_10_22391_920_287411 crossref_primary_10_3371_CSRP_HERA_020113 crossref_primary_10_1016_j_schres_2014_07_025 crossref_primary_10_1371_journal_pone_0090407 crossref_primary_10_1016_j_schres_2011_07_025 crossref_primary_10_3389_fimmu_2018_02230 crossref_primary_10_1016_j_bpsc_2016_08_007 crossref_primary_10_3389_fimmu_2018_00291 crossref_primary_10_1016_j_pnpbp_2012_08_015 crossref_primary_10_1016_j_psyneuen_2024_107062 crossref_primary_10_30569_adiyamansaglik_481915 crossref_primary_10_3389_fnins_2014_00331 crossref_primary_10_1016_j_neubiorev_2021_02_031 crossref_primary_10_1007_s00406_016_0759_5 crossref_primary_10_1016_j_psyneuen_2020_104744 crossref_primary_10_1007_s11682_020_00375_7 crossref_primary_10_1016_j_pnpbp_2018_04_004 crossref_primary_10_1111_pcn_12820 crossref_primary_10_1093_schbul_sbad082 crossref_primary_10_1186_1742_2094_9_56 crossref_primary_10_1016_j_schres_2012_10_041 crossref_primary_10_3389_fimmu_2023_1277959 crossref_primary_10_1038_s41398_020_0776_z crossref_primary_10_1097_01_XME_0000522264_90841 crossref_primary_10_1016_j_jpsychires_2012_04_026 crossref_primary_10_1016_j_pnpbp_2022_110646 crossref_primary_10_3390_jcm10112488 crossref_primary_10_1016_j_bbr_2020_113101 crossref_primary_10_1016_j_euroneuro_2020_10_005 crossref_primary_10_1016_j_procs_2022_11_074 crossref_primary_10_3389_fpsyt_2019_00005 crossref_primary_10_1016_j_nbd_2012_11_001 crossref_primary_10_1093_schbul_sby040 crossref_primary_10_1097_JCP_0000000000001253 crossref_primary_10_1111_cei_13334 crossref_primary_10_1007_s11011_012_9307_9 crossref_primary_10_1016_j_psychres_2018_11_043 crossref_primary_10_1007_s12640_017_9714_0 crossref_primary_10_1016_j_molmed_2018_09_002 crossref_primary_10_1016_j_pnpbp_2013_12_017 crossref_primary_10_1016_j_psychres_2020_112909 crossref_primary_10_1038_s41537_023_00424_2 crossref_primary_10_1093_schbul_sbx162 crossref_primary_10_1016_j_jprot_2020_103813 crossref_primary_10_3389_fpsyt_2019_00217 crossref_primary_10_1016_j_pharmthera_2022_108282 crossref_primary_10_1016_j_schres_2019_07_035 crossref_primary_10_3389_fnbeh_2019_00266 crossref_primary_10_1007_s00213_015_3975_1 crossref_primary_10_3889_oamjms_2021_7702 crossref_primary_10_1186_1741_7015_11_74 crossref_primary_10_1111_eip_12544 crossref_primary_10_3389_fpsyt_2021_696059 crossref_primary_10_1016_j_genhosppsych_2019_06_013 crossref_primary_10_1111_j_1399_0039_2012_01886_x crossref_primary_10_1016_j_pnpbp_2022_110626 crossref_primary_10_1002_wps_20144 crossref_primary_10_1016_j_schres_2017_04_043 crossref_primary_10_1038_s41398_021_01688_x crossref_primary_10_1093_schbul_sbx175 crossref_primary_10_1038_s41380_019_0479_0 crossref_primary_10_1093_schbul_sby021 crossref_primary_10_18632_oncotarget_17995 crossref_primary_10_3389_fpsyt_2020_00156 crossref_primary_10_1016_j_jpsychires_2015_10_015 crossref_primary_10_1038_s41398_023_02482_7 crossref_primary_10_1016_j_schres_2014_08_021 crossref_primary_10_1017_S0033291719003969 crossref_primary_10_1038_s41398_020_00949_5 crossref_primary_10_1016_j_jpsychires_2018_11_008 crossref_primary_10_1016_j_phrs_2020_104928 crossref_primary_10_1038_s41386_023_01705_1 crossref_primary_10_1016_j_neulet_2022_137011 crossref_primary_10_1038_s41380_018_0123_4 crossref_primary_10_1016_j_jpsychires_2012_11_007 crossref_primary_10_1016_j_schres_2015_10_001 crossref_primary_10_1002_ptr_8265 crossref_primary_10_1007_s12026_021_09238_9 crossref_primary_10_2217_bmm_13_83 crossref_primary_10_1093_schbul_sbw059 crossref_primary_10_1002_prca_201600021 crossref_primary_10_1016_j_schres_2015_10_008 crossref_primary_10_1007_s12031_015_0503_z crossref_primary_10_1097_NMD_0b013e31825bf9f7 crossref_primary_10_1016_j_schres_2015_02_004 crossref_primary_10_1016_S2215_0366_20_30042_0 crossref_primary_10_1016_j_mehy_2023_111158 crossref_primary_10_1007_s00420_018_1311_x crossref_primary_10_1177_0004867414533012 crossref_primary_10_1016_j_psychres_2018_05_063 crossref_primary_10_1097_PSY_0000000000000931 crossref_primary_10_3390_ijms22010188 crossref_primary_10_3390_ijms21144834 crossref_primary_10_18502_sjms_v13i4_3641 crossref_primary_10_1007_s43440_021_00269_5 crossref_primary_10_5455_bcp_20161123044657 crossref_primary_10_1016_j_psychres_2018_04_036 crossref_primary_10_1186_s13063_015_0580_x crossref_primary_10_1155_2013_257184 crossref_primary_10_1186_s12991_017_0128_4 crossref_primary_10_1371_journal_pone_0219139 crossref_primary_10_1038_s41398_022_01904_2 crossref_primary_10_1186_s12888_024_06277_y crossref_primary_10_1186_s12974_022_02541_8 crossref_primary_10_1016_j_bbi_2021_07_017 crossref_primary_10_1016_j_schres_2015_10_015 crossref_primary_10_1177_0706743718773728 crossref_primary_10_1016_j_cyto_2020_155366 crossref_primary_10_1093_schbul_sbw064 crossref_primary_10_1007_s00213_023_06346_2 crossref_primary_10_1016_j_cyto_2017_11_016 crossref_primary_10_1038_tp_2013_94 crossref_primary_10_1093_schbul_sbaa009 crossref_primary_10_1111_apt_16856 crossref_primary_10_1159_000356536 crossref_primary_10_3390_biomedicines11020454 crossref_primary_10_1093_schbul_sbu099 crossref_primary_10_1016_j_bbi_2024_06_017 crossref_primary_10_1016_j_schres_2017_06_007 crossref_primary_10_1016_j_schres_2020_02_007 crossref_primary_10_1016_j_jpsychires_2021_03_013 crossref_primary_10_1016_j_psyneuen_2015_03_003 crossref_primary_10_1016_j_schres_2017_11_023 crossref_primary_10_1016_j_schres_2022_06_026 crossref_primary_10_1007_s10571_021_01127_x crossref_primary_10_1016_j_biopsych_2013_12_002 crossref_primary_10_1016_j_biopsych_2013_12_006 crossref_primary_10_1016_j_schres_2023_11_012 crossref_primary_10_1007_s00213_014_3650_y crossref_primary_10_1136_gpsych_2021_100685 crossref_primary_10_1007_s11011_016_9822_1 crossref_primary_10_1016_j_schres_2020_02_010 crossref_primary_10_1016_j_schres_2013_09_021 crossref_primary_10_1016_j_schres_2015_10_038 crossref_primary_10_3389_fmicb_2022_845559 crossref_primary_10_1016_j_bbi_2015_09_014 crossref_primary_10_1016_j_comppsych_2020_152195 crossref_primary_10_1016_j_jad_2014_12_010 crossref_primary_10_1016_j_neuropharm_2017_06_003 crossref_primary_10_4306_pi_2017_14_4_383 crossref_primary_10_1111_nyas_13712 crossref_primary_10_1016_j_jad_2017_10_002 crossref_primary_10_1016_j_cyto_2017_04_025 crossref_primary_10_1590_1516_4446_2020_0950 crossref_primary_10_5498_wjp_v14_i6_794 crossref_primary_10_12956_tchd_1010956 crossref_primary_10_1177_0004867419835028 crossref_primary_10_1097_NMD_0000000000001624 crossref_primary_10_1016_j_rpsm_2016_04_003 crossref_primary_10_1038_s41398_021_01742_8 crossref_primary_10_1523_JNEUROSCI_1249_19_2019 crossref_primary_10_3389_fimmu_2019_02971 crossref_primary_10_1038_s41380_018_0058_9 crossref_primary_10_1038_s41398_023_02627_8 crossref_primary_10_1016_j_psyneuen_2014_09_031 crossref_primary_10_1016_j_scog_2015_06_002 crossref_primary_10_1016_j_psychres_2018_02_054 crossref_primary_10_1016_j_jpsychires_2012_12_010 crossref_primary_10_1155_2019_5601249 crossref_primary_10_1016_j_jneuroim_2016_05_010 crossref_primary_10_1186_s43045_024_00397_7 crossref_primary_10_1016_j_jpsychires_2018_12_015 crossref_primary_10_31363_2313_7053_2022_56_2_47_55 crossref_primary_10_3389_fphar_2020_00394 crossref_primary_10_3390_cells10020209 crossref_primary_10_1007_s00127_016_1297_1 crossref_primary_10_1016_j_jpsychires_2015_02_010 crossref_primary_10_3389_fpsyt_2018_00422 crossref_primary_10_1111_pcn_13078 crossref_primary_10_1038_s41398_020_01151_3 crossref_primary_10_1016_j_schres_2012_06_040 crossref_primary_10_1021_acsomega_1c03637 crossref_primary_10_1016_j_jpsychires_2012_12_001 crossref_primary_10_1093_ijnp_pyac026 crossref_primary_10_1134_S0026893320050118 crossref_primary_10_1016_j_schres_2019_08_005 crossref_primary_10_1136_ebmental_2018_300027 crossref_primary_10_2217_epi_14_26 crossref_primary_10_1038_s41398_021_01415_6 crossref_primary_10_1016_j_psychres_2018_03_045 crossref_primary_10_3389_fpsyt_2019_00605 crossref_primary_10_1016_j_bbi_2015_08_003 crossref_primary_10_3390_life11121365 crossref_primary_10_1016_j_jpsychires_2023_11_006 crossref_primary_10_1007_s12035_022_02976_3 crossref_primary_10_1016_j_psychres_2017_09_025 crossref_primary_10_1186_s12974_017_0962_y crossref_primary_10_1016_j_schres_2012_06_031 crossref_primary_10_1016_j_schres_2012_12_023 crossref_primary_10_1038_s41398_023_02505_3 crossref_primary_10_1212_NXI_0000000000000111 crossref_primary_10_1002_hup_2365 crossref_primary_10_1016_j_cyto_2012_10_028 crossref_primary_10_1038_s41598_017_07503_2 crossref_primary_10_1016_j_neuron_2022_01_033 crossref_primary_10_1093_schbul_sbu052 crossref_primary_10_3389_fpsyt_2022_1072380 crossref_primary_10_1038_mp_2016_248 crossref_primary_10_1038_mp_2016_247 crossref_primary_10_1016_j_cyto_2021_155441 crossref_primary_10_3390_neuroglia4010004 crossref_primary_10_1016_j_schres_2012_06_020 crossref_primary_10_1155_2016_3476240 crossref_primary_10_1016_j_isci_2021_103209 crossref_primary_10_3390_ijms22094675 crossref_primary_10_1038_tp_2015_91 crossref_primary_10_1080_15622975_2016_1224929 crossref_primary_10_1007_s00005_016_0434_6 crossref_primary_10_1016_j_rpsmen_2016_04_008 crossref_primary_10_1080_00207454_2020_1865952 crossref_primary_10_1016_j_psychres_2011_08_014 crossref_primary_10_1002_2211_5463_12704 crossref_primary_10_1016_j_schres_2017_06_034 crossref_primary_10_3390_genes13071200 crossref_primary_10_1186_s12888_018_1821_9 crossref_primary_10_1038_tp_2015_97 crossref_primary_10_3389_fgene_2019_00580 crossref_primary_10_1016_S2215_0366_23_00025_1 crossref_primary_10_18863_pgy_921569 crossref_primary_10_1038_s41398_021_01243_8 crossref_primary_10_1186_1471_244X_13_50 crossref_primary_10_1186_s41038_018_0133_0 crossref_primary_10_1007_s00213_020_05504_0 crossref_primary_10_1016_j_jpsychires_2020_11_028 crossref_primary_10_1016_j_pharmthera_2020_107480 crossref_primary_10_1016_j_schres_2017_08_027 crossref_primary_10_1016_j_schres_2022_12_028 crossref_primary_10_1371_journal_pone_0136372 crossref_primary_10_1016_j_psc_2016_01_003 crossref_primary_10_3390_ijms22115511 crossref_primary_10_1016_j_bbi_2015_12_010 crossref_primary_10_1111_bph_13364 crossref_primary_10_2147_NDT_S284149 crossref_primary_10_1111_acps_12799 crossref_primary_10_1093_schbul_sbv002 crossref_primary_10_1016_j_bbi_2021_08_209 crossref_primary_10_1016_j_pnpbp_2014_09_009 crossref_primary_10_1038_s41398_022_02228_x crossref_primary_10_1002_tkm2_1095 crossref_primary_10_1038_s41398_018_0366_5 crossref_primary_10_1016_j_genhosppsych_2015_03_017 crossref_primary_10_1016_j_jad_2014_10_030 crossref_primary_10_1371_journal_pone_0085945 crossref_primary_10_3389_fnins_2022_858989 crossref_primary_10_1038_npp_2017_258 crossref_primary_10_1016_j_bbi_2021_09_018 crossref_primary_10_3389_fpsyt_2018_00580 crossref_primary_10_1016_j_schres_2021_09_019 crossref_primary_10_1016_j_neuropharm_2021_108841 crossref_primary_10_1016_j_psychres_2023_115279 crossref_primary_10_1186_s12916_016_0712_5 crossref_primary_10_3389_fimmu_2020_01170 crossref_primary_10_1016_j_rpsm_2017_07_006 crossref_primary_10_1111_acps_13416 crossref_primary_10_1093_schbul_sbt070 crossref_primary_10_1016_j_psyneuen_2023_106386 crossref_primary_10_9758_cpn_2020_18_1_10 crossref_primary_10_1097_PSY_0000000000000529 crossref_primary_10_1016_j_jpsychires_2015_07_003 crossref_primary_10_1093_cercor_bhae255 crossref_primary_10_1007_s12031_018_1220_1 crossref_primary_10_1016_j_schres_2022_12_049 crossref_primary_10_1038_tp_2016_238 crossref_primary_10_1515_pterid_2016_0006 crossref_primary_10_1016_j_pnpbp_2011_11_003 crossref_primary_10_3389_fimmu_2020_02002 crossref_primary_10_1016_j_gene_2013_04_058 crossref_primary_10_1093_ijnp_pyaa006 crossref_primary_10_1111_acps_12783 crossref_primary_10_1007_s00213_016_4266_1 crossref_primary_10_1016_j_psyneuen_2020_104595 crossref_primary_10_1186_s12888_016_0866_x crossref_primary_10_3390_brainsci13030490 crossref_primary_10_1038_tp_2017_88 crossref_primary_10_1186_s12974_017_0938_y crossref_primary_10_1038_s41380_023_02213_w crossref_primary_10_3389_fpsyt_2021_728990 crossref_primary_10_1016_j_psychres_2015_07_029 crossref_primary_10_3389_fpsyt_2021_666067 crossref_primary_10_1186_1745_6215_16_9 crossref_primary_10_1134_S1819712423010166 crossref_primary_10_1016_j_biopsych_2013_06_010 crossref_primary_10_1016_j_jad_2015_04_044 crossref_primary_10_1016_j_psc_2016_01_011 crossref_primary_10_1016_j_psychres_2022_114938 crossref_primary_10_1017_S0033291721000155 crossref_primary_10_54005_geneltip_1538269 crossref_primary_10_1016_j_ebiom_2018_11_064 crossref_primary_10_1155_2013_125264 crossref_primary_10_1515_revneuro_2013_0045 crossref_primary_10_1016_j_bbih_2019_100034 crossref_primary_10_1093_schbul_sbaa190 crossref_primary_10_3390_brainsci12121703 crossref_primary_10_1016_j_bbi_2024_08_013 crossref_primary_10_1111_pcn_12290 crossref_primary_10_1007_s11011_025_01558_1 crossref_primary_10_1038_tp_2015_204 crossref_primary_10_1002_jdn_10058 crossref_primary_10_3390_microarrays5010006 crossref_primary_10_1016_j_intell_2018_03_002 crossref_primary_10_1176_appi_ajp_2015_14101358 crossref_primary_10_1016_j_bbih_2025_100959 crossref_primary_10_1016_j_euroneuro_2022_12_008 crossref_primary_10_1016_j_brainresbull_2024_111104 crossref_primary_10_1007_s11126_018_9591_6 crossref_primary_10_1186_s12974_014_0187_2 crossref_primary_10_1016_j_jpsychires_2021_04_029 crossref_primary_10_1515_mr_2022_0009 crossref_primary_10_3389_fphar_2021_682602 crossref_primary_10_1017_neu_2021_13 crossref_primary_10_1016_j_psychres_2015_08_006 crossref_primary_10_1002_ajmg_b_32350 crossref_primary_10_1093_schbul_sbu110 crossref_primary_10_1016_j_encep_2019_11_007 crossref_primary_10_1016_j_jad_2012_06_010 crossref_primary_10_1371_journal_pone_0124597 crossref_primary_10_1016_j_schres_2018_02_048 crossref_primary_10_1016_j_psychres_2016_01_018 crossref_primary_10_1111_pcn_12040 crossref_primary_10_1007_s00213_017_4683_9 crossref_primary_10_1016_j_scog_2024_100304 crossref_primary_10_1038_s41537_019_0090_z crossref_primary_10_1016_j_bbi_2022_03_016 crossref_primary_10_1097_PSY_0000000000000339 crossref_primary_10_1146_annurev_devpsych_050620_030405 crossref_primary_10_1007_s00213_013_3382_4 crossref_primary_10_1192_apt_bp_114_012872 crossref_primary_10_1155_2019_4042615 crossref_primary_10_3390_cimb45010035 crossref_primary_10_1093_schbul_sbaa134 crossref_primary_10_1093_schbul_sbu118 crossref_primary_10_1093_schbul_sbaa136 crossref_primary_10_1038_tp_2016_229 crossref_primary_10_1016_j_ajp_2017_03_027 crossref_primary_10_1016_j_psyneuen_2023_106109 crossref_primary_10_1007_s12035_018_0940_0 crossref_primary_10_1038_mp_2016_180 crossref_primary_10_1038_s41380_023_02059_2 crossref_primary_10_1016_j_pnpbp_2011_12_002 crossref_primary_10_3389_fnsys_2021_704069 crossref_primary_10_1016_j_cyto_2014_05_008 crossref_primary_10_1016_j_schres_2015_05_034 crossref_primary_10_1016_j_jaac_2016_12_010 crossref_primary_10_1016_j_jneuroim_2022_577881 crossref_primary_10_1016_j_pnpbp_2020_110013 crossref_primary_10_3371_CSRP_MICU_020813 crossref_primary_10_1016_j_euroneuro_2021_09_003 crossref_primary_10_3109_15622975_2012_747699 crossref_primary_10_31857_S0016675823100107 crossref_primary_10_3390_molecules25225388 crossref_primary_10_1016_j_jpsychires_2013_05_032 crossref_primary_10_1016_j_schres_2017_08_040 crossref_primary_10_1016_j_schres_2014_10_055 crossref_primary_10_1038_npp_2016_211 crossref_primary_10_1016_j_psychres_2015_08_029 crossref_primary_10_1038_s41380_021_01362_0 crossref_primary_10_1038_s41398_022_01889_y crossref_primary_10_1016_j_psyneuen_2023_106335 crossref_primary_10_1016_j_jadr_2023_100597 crossref_primary_10_54005_geneltip_1032165 crossref_primary_10_3389_fncel_2024_1345349 crossref_primary_10_1038_s41380_018_0306_z crossref_primary_10_17816_CP66 crossref_primary_10_7717_peerj_4214 crossref_primary_10_1016_j_schres_2013_01_026 crossref_primary_10_1016_j_jpsychires_2012_08_016 crossref_primary_10_1016_j_schres_2017_08_038 crossref_primary_10_3390_nu16071039 crossref_primary_10_1080_08820139_2016_1237523 crossref_primary_10_3390_cells9040870 crossref_primary_10_1016_j_psychres_2021_113745 crossref_primary_10_3390_ijms221910254 crossref_primary_10_1155_2017_5763094 crossref_primary_10_1002_dneu_22044 crossref_primary_10_1016_j_ajp_2016_11_010 crossref_primary_10_2174_1570159X21666230817153631 crossref_primary_10_1016_j_psychres_2015_08_018 crossref_primary_10_1016_j_jpsychires_2016_01_013 crossref_primary_10_1097_MD_0000000000038677 crossref_primary_10_1007_s40263_015_0233_3 crossref_primary_10_3390_ijms18030651 crossref_primary_10_1016_j_rpsm_2018_03_004 crossref_primary_10_1038_tp_2017_4 crossref_primary_10_1016_j_neubiorev_2013_11_006 crossref_primary_10_1007_s12264_020_00535_1 crossref_primary_10_1016_j_amp_2021_09_019 crossref_primary_10_1016_j_neuroscience_2014_06_028 crossref_primary_10_1016_j_ajp_2019_09_026 crossref_primary_10_1016_j_schres_2018_04_017 crossref_primary_10_1016_j_patbio_2014_10_003 crossref_primary_10_1080_13651501_2022_2101928 crossref_primary_10_1016_j_intimp_2023_111308 crossref_primary_10_1093_schizbullopen_sgaa026 crossref_primary_10_3389_fpsyt_2020_00046 crossref_primary_10_1038_s41398_024_03021_8 crossref_primary_10_3389_fimmu_2017_00618 crossref_primary_10_1038_npp_2017_7 crossref_primary_10_3389_fnut_2024_1397544 crossref_primary_10_1016_j_psychres_2020_113421 crossref_primary_10_3390_jcm11010232 crossref_primary_10_1038_s41598_021_98769_0 crossref_primary_10_1016_j_biopha_2020_111200 crossref_primary_10_1016_j_pbb_2023_173593 crossref_primary_10_1016_j_schres_2017_09_002 crossref_primary_10_1007_s11306_024_02088_0 crossref_primary_10_1159_000485130 crossref_primary_10_3389_fnins_2018_01011 crossref_primary_10_1016_j_psyneuen_2024_107134 crossref_primary_10_1016_j_neubiorev_2017_03_003 crossref_primary_10_1016_j_psyneuen_2024_107135 crossref_primary_10_1080_15622975_2016_1212172 crossref_primary_10_1016_j_bbih_2022_100459 crossref_primary_10_1590_1516_4446_2020_1670 crossref_primary_10_3390_nu15204391 crossref_primary_10_1016_j_biopsych_2013_01_001 crossref_primary_10_5498_wjp_v6_i1_31 crossref_primary_10_1016_j_bbi_2014_01_018 crossref_primary_10_1007_s00406_019_01073_2 crossref_primary_10_18632_aging_102692 crossref_primary_10_1038_s41398_018_0299_z crossref_primary_10_3389_fpsyt_2018_00155 crossref_primary_10_1016_j_schres_2018_01_018 crossref_primary_10_1016_j_bbi_2025_03_002 crossref_primary_10_1016_j_psyneuen_2015_08_017 crossref_primary_10_1016_j_psyneuen_2018_02_031 crossref_primary_10_1016_j_schres_2018_01_015 crossref_primary_10_3389_fphar_2022_895668 crossref_primary_10_1016_j_bbagen_2018_12_008 crossref_primary_10_1016_j_pnpbp_2012_07_016 crossref_primary_10_1016_j_scog_2024_100328 crossref_primary_10_1186_s12974_018_1197_2 crossref_primary_10_3390_ijerph19073781 crossref_primary_10_1002_rcm_7753 crossref_primary_10_1177_0884533613493333 crossref_primary_10_3389_fpsyt_2019_00131 crossref_primary_10_1016_j_euroneuro_2015_06_011 crossref_primary_10_12779_dnd_2015_14_1_1 crossref_primary_10_1177_0269881114566631 crossref_primary_10_1016_j_jddst_2022_104064 crossref_primary_10_1038_s41398_020_0802_1 crossref_primary_10_1016_j_schres_2020_10_003 crossref_primary_10_15789_1563_0625_AOI_2528 crossref_primary_10_1016_j_schres_2015_05_005 crossref_primary_10_3390_ijms26010310 crossref_primary_10_1097_PSY_0000000000000352 crossref_primary_10_3389_fpsyt_2017_00174 crossref_primary_10_1016_j_schres_2018_01_002 crossref_primary_10_1590_1516_4446_2019_0699 crossref_primary_10_3389_fpsyt_2022_957671 crossref_primary_10_1111_bph_13772 crossref_primary_10_1016_j_schres_2018_04_026 crossref_primary_10_1126_sciadv_aau9093 crossref_primary_10_1016_j_neubiorev_2021_01_018 crossref_primary_10_1134_S1022795423100101 crossref_primary_10_1007_s00702_015_1492_3 crossref_primary_10_1001_jamapsychiatry_2020_2459 crossref_primary_10_1016_j_biopsych_2013_01_007 crossref_primary_10_3390_ijms25158477 crossref_primary_10_1016_j_bbih_2022_100436 crossref_primary_10_1016_j_pnpbp_2012_07_009 crossref_primary_10_1155_2023_7017106 crossref_primary_10_1186_s12974_019_1408_5 crossref_primary_10_1007_s40291_021_00516_8 crossref_primary_10_1016_j_cyto_2019_154740 crossref_primary_10_1016_j_bbih_2021_100392 crossref_primary_10_1016_j_psychres_2018_07_041 crossref_primary_10_1016_j_npbr_2019_10_002 crossref_primary_10_3390_v15061345 crossref_primary_10_1016_S2215_0366_20_30564_2 crossref_primary_10_1111_acps_13212 crossref_primary_10_9758_cpn_2017_15_3_237 crossref_primary_10_1016_j_nicl_2013_04_012 crossref_primary_10_3390_antiox12040975 crossref_primary_10_1021_acs_jproteome_7b00279 crossref_primary_10_1017_S0033291716000659 crossref_primary_10_1016_j_neubiorev_2019_06_020 crossref_primary_10_1093_ijnp_pyv096 crossref_primary_10_1080_1028415X_2023_2233176 crossref_primary_10_1177_08850666231201567 crossref_primary_10_3390_metabo12100983 crossref_primary_10_3390_biomedicines12122884 crossref_primary_10_3928_00485713_20180416_01 crossref_primary_10_1016_j_biopsych_2012_09_007 crossref_primary_10_4274_BMJ_galenos_2022_2021_11_9 crossref_primary_10_1038_srep26105 crossref_primary_10_4236_health_2015_710144 crossref_primary_10_1016_j_jpsychires_2021_07_011 crossref_primary_10_3389_fpsyt_2020_580503 crossref_primary_10_1016_j_psychres_2017_11_033 crossref_primary_10_1016_j_ejphar_2015_08_046 crossref_primary_10_1016_j_schres_2014_12_037 crossref_primary_10_1586_14737175_2013_811191 crossref_primary_10_1111_psyp_12353 crossref_primary_10_1016_j_schres_2015_07_018 crossref_primary_10_1111_acps_13458 crossref_primary_10_4236_abb_2012_324072 crossref_primary_10_1007_s12668_017_0392_4 crossref_primary_10_1016_j_schres_2015_07_010 crossref_primary_10_1016_j_jpsychires_2014_10_011 crossref_primary_10_1007_s00281_022_00948_2 crossref_primary_10_1017_S0954579420001157 crossref_primary_10_1038_mp_2015_87 crossref_primary_10_1093_ijnp_pyx015 crossref_primary_10_3389_fpsyt_2021_612471 crossref_primary_10_3934_publichealth_2014_2_43 crossref_primary_10_1016_j_schres_2013_03_027 crossref_primary_10_1016_j_bbi_2018_09_016 crossref_primary_10_1016_j_pnpbp_2012_06_014 crossref_primary_10_1016_S2215_0366_14_00122_9 crossref_primary_10_1016_j_pnpbp_2024_111221 crossref_primary_10_1007_s13668_013_0054_2 crossref_primary_10_1016_j_tins_2012_08_001 crossref_primary_10_1038_s41582_020_0364_0 crossref_primary_10_1016_j_schres_2020_11_009 crossref_primary_10_3389_fnins_2021_678548 crossref_primary_10_3389_fmicb_2023_1132866 crossref_primary_10_1016_j_neubiorev_2014_06_004 crossref_primary_10_1186_s12974_022_02648_y crossref_primary_10_3389_fphar_2020_594394 crossref_primary_10_1038_mp_2015_90 crossref_primary_10_1016_j_biopsych_2014_10_014 crossref_primary_10_1016_j_bbi_2018_08_009 crossref_primary_10_1016_j_schres_2015_06_009 crossref_primary_10_1016_j_psyneuen_2018_02_001 crossref_primary_10_1038_mp_2015_79 crossref_primary_10_1016_j_jphs_2017_01_004 crossref_primary_10_1007_s10072_011_0712_3 crossref_primary_10_3389_fpsyt_2021_771144 crossref_primary_10_3109_15622975_2015_1062552 crossref_primary_10_1016_j_brainresbull_2023_110820 crossref_primary_10_1017_S0033291718000831 crossref_primary_10_1155_2018_3502564 crossref_primary_10_31857_S1027813323010168 crossref_primary_10_1159_000492716 crossref_primary_10_2174_1570159X17666190603170511 crossref_primary_10_3389_fnins_2017_00155 crossref_primary_10_5498_wjp_v12_i9_1183 crossref_primary_10_1093_sexmed_qfaf002 crossref_primary_10_31363_2313_7053_2022_56_4_52_62 crossref_primary_10_18632_oncotarget_13551 crossref_primary_10_1016_j_schres_2019_11_033 |
| Cites_doi | 10.1017/S1461145709000315 10.1192/bjp.157.1.136 10.1111/1468-2389.00156 10.1016/j.cyto.2009.05.005 10.1016/S0920-9964(97)00057-1 10.1007/BF02190412 10.1017/S026418010000059X 10.1016/S0165-1781(97)00036-X 10.1016/S0920-9964(00)00007-4 10.1001/archpsyc.1967.01730190003001 10.1016/S0278-5846(97)00082-1 10.1159/000213565 10.1192/bjp.164.2.251 10.1054/mehy.2000.1203 10.1016/S0022-3956(99)00021-7 10.1016/j.plefa.2003.08.015 10.1001/archpsyc.1967.01730190026003 10.1016/j.jpsychires.2009.10.011 10.1016/0920-9964(92)90006-Q 10.1002/ajmg.1320600517 10.1016/j.intimp.2005.10.004 10.1177/0269881107077609 10.1007/BF02900219 10.1159/000067805 10.1016/S0920-9964(01)00296-1 10.1016/0920-9964(91)90073-Z 10.1016/j.psychres.2004.04.012 10.1038/mp.2009.52 10.1111/j.1600-0447.1994.tb01599.x 10.1016/j.biopsych.2007.09.024 10.1016/j.psychres.2006.08.005 10.1016/S0920-9964(97)00008-X 10.1001/archpsyc.60.12.1187 10.1016/S0924-977X(99)00062-0 10.1016/S0920-9964(97)00059-5 10.1016/S0920-9964(98)00034-6 10.1016/j.psychres.2007.11.014 10.1016/j.schres.2010.04.015 10.1038/sj.mp.4001084 10.1016/0920-9964(96)00029-1 10.1176/ajp.156.11.1725 10.1016/j.pnpbp.2004.05.047 10.1016/j.humimm.2009.09.351 10.1007/s004060050051 10.1016/S0920-9964(00)00094-3 10.1007/BF00920636 10.1016/j.biopsych.2008.10.018 10.1080/09629350123895 10.1111/j.1440-1819.2009.01945.x 10.1160/TH08-07-0421 10.1515/JBCPP.1995.6.1.61 10.1016/0920-9964(96)00014-X 10.1016/S0920-9964(99)00171-1 10.1016/j.biopsych.2008.04.005 10.1016/S0278-5846(01)00221-4 10.1001/archpsyc.1989.01810030097017 10.1001/archpsyc.1989.01810030098018 10.1016/j.jpsychires.2009.08.008 10.1176/appi.ajp.159.6.1029 10.1016/j.schres.2006.02.003 10.1001/archpsyc.1967.01730190012002 10.1007/s00213-008-1295-4 10.1016/0022-3956(94)00049-W 10.1192/bjp.bp.108.052605 10.1017/S0033291700027410 10.1007/BF02922260 10.1016/0306-9877(95)90062-4 10.1111/j.1399-5618.2009.00757.x 10.1176/ajp.152.9.1291 10.4088/JCP.v65n0710 10.1016/S0165-1781(99)00053-0 10.1016/j.schres.2006.11.016 10.1006/exnr.1996.0200 10.1016/S0893-133X(96)00143-1 10.1016/0006-3223(94)91137-1 10.4088/JCP.09m05117yel 10.1016/S0920-9964(98)00140-6 10.1016/j.bbi.2009.04.005 10.1016/0024-3205(91)90112-O 10.1055/s-2004-832668 10.1016/0920-9964(95)00089-5 10.1177/147323000203000313 10.1016/0278-5846(93)90072-Z 10.1016/S0920-9964(00)00156-0 10.1038/sj.npp.1300756 10.1016/0165-1781(94)90042-6 10.1016/S0924-9338(97)84789-X 10.1176/ajp.142.10.1184 10.1038/sj.npp.1300217 10.1016/j.schres.2008.03.018 10.1016/j.schres.2008.09.001 10.1007/s00406-004-0478-1 10.1177/0269881108089583 10.1006/jaut.1996.0086 10.1007/s00213-008-1447-6 10.3109/00207450108986549 10.1159/000148197 10.1111/j.1600-0447.1994.tb01527.x 10.1007/BF02190280 10.1159/000119130 10.1007/BF02191517 10.1176/ajp.150.9.1408 |
| ContentType | Journal Article |
| Copyright | 2011 Society of Biological Psychiatry Society of Biological Psychiatry Copyright © 2011 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved. 2011 Society of Biological Psychiatry 2011 |
| Copyright_xml | – notice: 2011 Society of Biological Psychiatry – notice: Society of Biological Psychiatry – notice: Copyright © 2011 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved. – notice: 2011 Society of Biological Psychiatry 2011 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| DOI | 10.1016/j.biopsych.2011.04.013 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Chemistry Biology |
| EISSN | 1873-2402 |
| EndPage | 671 |
| ExternalDocumentID | PMC4071300 21641581 10_1016_j_biopsych_2011_04_013 S0006322311004045 1_s2_0_S0006322311004045 |
| Genre | Meta-Analysis Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NIAID NIH HHS grantid: AI075165 – fundername: NIAID NIH HHS grantid: R01 AI075165 – fundername: NIAID NIH HHS grantid: AI083005 – fundername: NIAID NIH HHS grantid: U01 AI083005 |
| GroupedDBID | --- --K --M -DZ .1- .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 23N 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 6J9 7-5 71M 8P~ 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAXKI AAXLA AAXUO AAYWO ABBQC ABCQJ ABCQX ABDPE ABFNM ABFRF ABIVO ABJNI ABLJU ABMAC ABMZM ABWVN ABXDB ACDAQ ACGFO ACIEU ACIUM ACNCT ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AGUBO AGWIK AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HEG HMK HMO HMQ HVGLF HZ~ H~9 IHE J1W KOM L7B M29 M2V M39 M41 MO0 MOBAO N9A O-L O9- OAUVE OH0 OU- OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SEL SES SNS SPCBC SSH SSN SSZ T5K UAP UNMZH UPT UV1 WH7 WUQ XJT XOL Z5R ZCA ZGI ZKB ZXP ~G- AACTN AFCTW AFKWA AJOXV AMFUW PKN RIG AADPK AAIAV ABLVK ABYKQ AJBFU EFLBG G8K LCYCR ZA5 AAYXX AGRNS CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c646t-fc4216aec5a4963d0d2ffa888243fb01f80e17e27b812fa5fea44bbc89cc41a13 |
| IEDL.DBID | .~1 |
| ISSN | 0006-3223 1873-2402 |
| IngestDate | Thu Aug 21 18:21:36 EDT 2025 Fri Jul 11 14:45:58 EDT 2025 Thu Apr 03 06:57:02 EDT 2025 Thu Apr 24 22:53:01 EDT 2025 Tue Jul 01 03:38:05 EDT 2025 Fri Feb 23 02:26:57 EST 2024 Sun Feb 23 10:19:27 EST 2025 Tue Aug 26 16:32:00 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Keywords | meta-analysis schizophrenia Cytokines relapse first-episode psychosis |
| Language | English |
| License | https://www.elsevier.com/tdm/userlicense/1.0 Copyright © 2011 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c646t-fc4216aec5a4963d0d2ffa888243fb01f80e17e27b812fa5fea44bbc89cc41a13 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | http://doi.org/10.1016/j.biopsych.2011.04.013 |
| PMID | 21641581 |
| PQID | 892947188 |
| PQPubID | 23479 |
| PageCount | 9 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4071300 proquest_miscellaneous_892947188 pubmed_primary_21641581 crossref_citationtrail_10_1016_j_biopsych_2011_04_013 crossref_primary_10_1016_j_biopsych_2011_04_013 elsevier_sciencedirect_doi_10_1016_j_biopsych_2011_04_013 elsevier_clinicalkeyesjournals_1_s2_0_S0006322311004045 elsevier_clinicalkey_doi_10_1016_j_biopsych_2011_04_013 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2011-10-01 |
| PublicationDateYYYYMMDD | 2011-10-01 |
| PublicationDate_xml | – month: 10 year: 2011 text: 2011-10-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Biological psychiatry (1969) |
| PublicationTitleAlternate | Biol Psychiatry |
| PublicationYear | 2011 |
| Publisher | Elsevier Inc |
| Publisher_xml | – name: Elsevier Inc |
| References | Rapaport, McAllister, Kim, Han, Pickar, Nelson (bib74) 1994; 35 Zhang, Zhou, Cao, Zhang, Wu, Shen (bib95) 2004; 65 Rapaport, McAllister, Pickar, Tamarkin, Kirch, Paul (bib77) 1997; 25 Vawter, Dillon-Carter, Issa, Wyatt, Freed (bib89) 1997; 16 Licinio, Seibyl, Altemus, Charney, Krystal (bib51) 1993; 150 Hope, Melle, Aukrust, Steen, Birkenaes, Lorentzen (bib43) 2009; 11 Akhondzadeh, Tabatabaee, Amini (bib9) 2007; 90 Theodoropoulou, Spanakos, Baxevanis, Economou, Gritzapis, Papamichail, Stefanis (bib87) 2001; 47 García-Miss Mdel, Pérez-Mutul, López-Canul, Solís-Rodríguez, Puga-Machado, Oxté-Cabrera (bib40) 2010; 44 Nimgaonkar, Yang, Zhang, Brar, Chakravarti, Ganguli (bib68) 1995; 60 Drexhage, Hoogenboezem, Cohen, Versnel, Nolen, van Beveren, Drexhage (bib107) 2011; 24 Yang, Chengappa, Shurin, Brar, Rabin, Gubbi, Ganguli (bib91) 1994; 24 Heath, Krupp (bib2) 1967; 16 Barry, Clarke, Scully, Dinan (bib22) 2009; 23 Akiyama (bib23) 1999; 37 Haack, Hinze-Selch, Fenzel, Kraus, Kühn, Schuld (bib42) 1999; 33 Xu, Wei, Hemmings (bib94) 1994; 164 Garver, Tamas, Holcomb (bib6) 2003; 28 Zhang, Zhou, Cao, Wu, Shen (bib96) 2005; 30 Nikkilä, Ahokas, Wahlbeck, Rimón, Andersson (bib67) 2002; 46 Katila, Hurme, Wahlbeck, Appelberg, Rimón (bib45) 1994; 30 Hunter, Schmidt (bib99) 2000; 8 Ganguli, Yang, Shurin, Chengappa, Brar, Gubbi, Rabin (bib39) 1994; 51 Singh, Bera, Nayak, Chaudhuri (bib83) 2009; 47 Cazzullo, Sacchetti, Galluzzo, Panariello, Adorni, Pegoraro (bib29) 2002; 26 Rapaport, McAllister, Pickar, Nelson, Paul (bib72) 1989; 46 Wilke, Arolt, Rothermundt, Weitzsch, Hornberg, Kirchner (bib20) 1996; 246 Wyatt (bib105) 1991; 5 Ganguli, Rabin (bib38) 1989; 46 Monteleone, Fabrazzo, Tortorella, Maj (bib61) 1997; 71 Coelho, Reis, Nicolato, Romano-Silva, Teixeira, Bauer, Teixeira (bib30) 2008; 15 O'Connor, Bower, Cho, Creswell, Dimitrov, Hamby (bib17) 2009; 23 Maes, Bosmans, Kenis, De Jong, Smith, Meltzer (bib58) 1997; 26 al-Janadi, al-Balla, al-Dalaan, Raziuddin (bib100) 1993; 13 Schwarz, Riedel, Gruber, Müller, Ackenheil (bib21) 1998; 248 Müller, Dobmeier, Empl, Riedel, Schwarz, Ackenheil (bib62) 1997; 12 Fernandez-Egea, Bernardo, Donner, Congent, Parellada, Justicia (bib36) 2009; 194 Frommberger, Bauer, Haselbauer, Fräulin, Riemann, Berger (bib37) 1997; 247 Xiu, Chen, Wang, Cao, Qi, Chen da (bib90) 2008; 106 Monji, Kato, Kanba (bib16) 2009; 63 Kim, Suh, Kim, Han, Lim, Choi, Licinio (bib48) 2002; 7 Maes, Bosmans, Ranjan, Vandoolaeghe, Meltzer, De Ley (bib57) 1996; 21 Ebrinç, Top, Oncül, Başoğlu, Cavuşlu, Cetin (bib33) 2002; 30 Bechter, Reiber, Herzog, Fuchs, Tumani, Maxeiner (bib26) 2010; 44 Bresee, Rapaport (bib28) 2009; 12 Smith, Maes (bib14) 1995; 45 Yao, Sistilli, van Kammen (bib92) 2003; 69 Müller, Riedel, Scheppach, Brandstätter, Sokullu, Krampe (bib11) 2002; 159 Müller, Krause, Dehning, Musil, Schennach-Wolff, Obermeier (bib12) 2010; 121 Heath, Krupp, Byers, Lijekvist (bib4) 1967; 16 Müller, Ulmschneider, Scheppach, Schwarz, Ackenheil, Möller (bib13) 2004; 254 Shintani, Kanba, Maruo, Nakaki, Nibuya, Suzuki (bib82) 1991; 49 Naudin, Capo, Giusano, Mege, Azorin (bib65) 1997; 26 Potvin, Stip, Sepehry, Gendron, Bah, Kouassi (bib5) 2008; 63 Laan, Grobbee, Selten, Heijnen, Kahn, Burger (bib10) 2010; 71 Kim, Kim, Lee (bib46) 2000; 44 Kim, Myint, Lee, Han, Lee, Kim, Leonard (bib49) 2004; 28 Shepherd, Watt, Falloon, Smeeton (bib104) 1989; 15 Zhang, Cao, Song, Wu, Chen da, Qi (bib97) 2008; 201 Ganguli, Gubbi (bib102) 1997; 18 Maes, Bocchio Chiavetto, Bignotti, Battisa Tura, Pioli, Boin (bib60) 2002; 54 Schattner, Cori, Hahn, Sirota (bib80) 1996; 9 Erbağci, Herken, Köylüoglu, Yilmaz, Tarakçioglu (bib35) 2001; 10 Manavalan, Hernandez, Shah, Konikkara, Naiyer, Lee (bib101) 2010; 71 Naudin, Mège, Azorin, Dassa (bib64) 1996; 20 Nikkilä, Müller, Ahokas, Miettinen, Rimón, Andersson (bib66) 1999; 156 Schwarz, Müller, Riedel, Ackenheil (bib15) 2001; 56 Rapaport, Caligiuri, Lohr (bib76) 1997; 21 Schwarz, Riedel, Gruber, Müller, Ackenheil (bib81) 1998; 248 Zhang, Zhou, Qi, Chen, Cao, Chen da (bib98) 2009; 204 Song, Lv, Li, Hao, Zhao (bib86) 2009; 65 Kim, Kim, Yoon, Go, Choi, Jun, Kim (bib47) 2001; 111 Preble, Torrey (bib71) 1985; 142 Zhang, Zhou, Zhang, WuGY, Cao, Shen (bib93) 2002; 57 Rapaport, Lohr (bib75) 1994; 90 el-Mallakh, Suddath, Wyatt (bib34) 1993; 17 Baker, Masserano, Wyatt (bib24) 1996; 20 Dickinson, Ragland, Gold, Gur (bib1) 2008; 64 Kaminska, Wysocka, Marmurowska-Michalowska, Dubas-Slemp, Kandefer-Szerszen (bib44) 2001; 49 Drexhage, Padmos, de Wit, Versnel, Hooijkaas, van der Lely (bib32) 2008; 102 Müller, Empl, Riedel, Schwarz, Ackenheil (bib63) 1997; 247 Maes, Meltzer, Bosmans (bib54) 1994; 89 McAllister, van Kammen, Rehn, Miller, Gurklis, Kelley (bib78) 1995; 152 Sirota, Meiman, Herschko, Bessler (bib84) 2005; 134 Müller (bib103) 2004; 37 Rapaport, Torrey, McAllister, Nelson, Pickar, Paul (bib73) 1993; 243 Vawter, Dillon-Carter, Tourtellotte, Carvey, Freed (bib88) 1996; 142 Lu, Liu, Kong, Chen Shen, Chen, Yao (bib53) 2003; 17 Sarandol, Kirli, Akkaya, Ocak, Eroz, Sarandol (bib79) 2007; 21 O'Brien, Scully, Dinan (bib69) 2008; 160 Pae, Yoon, Kim, Kim, Park, Lee (bib70) 2006; 6 Crespo-Facorro, Carrasco-Marín, Pérez-Iglesias, Pelayo-Terán, Fernandez-Prieto, Leyva-Cobián, Vázquez-Barquero (bib31) 2008; 158 Barak, Barak, Levine, Nisman, Roisman (bib25) 1995; 6 Maes, Meltzer, Buckley, Bosmans (bib55) 1995; 244 Becker, Kritschmann, Floru, Shlomo-David, Gotlieb-Stematsky (bib27) 1990; 157 Adib-Conquy, Cavaillon (bib106) 2009; 101 Söderlund, Schröder, Nordin, Samuelsson, Walther-Jallow, Karlsson (bib85) 2009; 14 Maes, Bosmans, Calabrese, Smith, Meltzer (bib56) 1995; 29 van Kammen, McAllister-Sistilli, Kelley, Gurklis, Yao (bib7) 1999; 87 Gattaz, Dalgalarrondo, Schröder (bib41) 1992; 6 Kowalski, Blada, Kucia, Madej, Herman (bib19) 2001; 50 Maes, Bocchio Chiavetto, Bignotti, Battisa Tura, Pioli, Boin (bib59) 2000; 10 Heath, Krupp, Byers, Liljekvist (bib3) 1967; 16 Kim, Myint, Verkerk, Scharpe, Steinbusch, Leonard (bib50) 2009; 59 Nunes, Matsuo, Kaminami, Watanabe, Reiche, Itano (bib8) 2006; 84 Sullivan, Kendler, Neale (bib18) 2003; 60 Lin, Kenis, Bignotti, Tura, De Jong, Bosmans (bib52) 1998; 32 Kim (10.1016/j.biopsych.2011.04.013_bib48) 2002; 7 Heath (10.1016/j.biopsych.2011.04.013_bib2) 1967; 16 Rapaport (10.1016/j.biopsych.2011.04.013_bib75) 1994; 90 Licinio (10.1016/j.biopsych.2011.04.013_bib51) 1993; 150 Cazzullo (10.1016/j.biopsych.2011.04.013_bib29) 2002; 26 Gattaz (10.1016/j.biopsych.2011.04.013_bib41) 1992; 6 Frommberger (10.1016/j.biopsych.2011.04.013_bib37) 1997; 247 Theodoropoulou (10.1016/j.biopsych.2011.04.013_bib87) 2001; 47 Song (10.1016/j.biopsych.2011.04.013_bib86) 2009; 65 Hunter (10.1016/j.biopsych.2011.04.013_bib99) 2000; 8 Crespo-Facorro (10.1016/j.biopsych.2011.04.013_bib31) 2008; 158 Monji (10.1016/j.biopsych.2011.04.013_bib16) 2009; 63 Heath (10.1016/j.biopsych.2011.04.013_bib3) 1967; 16 Lu (10.1016/j.biopsych.2011.04.013_bib53) 2003; 17 Coelho (10.1016/j.biopsych.2011.04.013_bib30) 2008; 15 Garver (10.1016/j.biopsych.2011.04.013_bib6) 2003; 28 Akiyama (10.1016/j.biopsych.2011.04.013_bib23) 1999; 37 Erbağci (10.1016/j.biopsych.2011.04.013_bib35) 2001; 10 Kim (10.1016/j.biopsych.2011.04.013_bib50) 2009; 59 Vawter (10.1016/j.biopsych.2011.04.013_bib88) 1996; 142 Monteleone (10.1016/j.biopsych.2011.04.013_bib61) 1997; 71 Maes (10.1016/j.biopsych.2011.04.013_bib57) 1996; 21 Schwarz (10.1016/j.biopsych.2011.04.013_bib21) 1998; 248 Ganguli (10.1016/j.biopsych.2011.04.013_bib38) 1989; 46 O'Brien (10.1016/j.biopsych.2011.04.013_bib69) 2008; 160 Xiu (10.1016/j.biopsych.2011.04.013_bib90) 2008; 106 Fernandez-Egea (10.1016/j.biopsych.2011.04.013_bib36) 2009; 194 Ganguli (10.1016/j.biopsych.2011.04.013_bib39) 1994; 51 Müller (10.1016/j.biopsych.2011.04.013_bib103) 2004; 37 Katila (10.1016/j.biopsych.2011.04.013_bib45) 1994; 30 Kim (10.1016/j.biopsych.2011.04.013_bib47) 2001; 111 O'Connor (10.1016/j.biopsych.2011.04.013_bib17) 2009; 23 Wilke (10.1016/j.biopsych.2011.04.013_bib20) 1996; 246 Vawter (10.1016/j.biopsych.2011.04.013_bib89) 1997; 16 Adib-Conquy (10.1016/j.biopsych.2011.04.013_bib106) 2009; 101 Yao (10.1016/j.biopsych.2011.04.013_bib92) 2003; 69 Zhang (10.1016/j.biopsych.2011.04.013_bib93) 2002; 57 Barry (10.1016/j.biopsych.2011.04.013_bib22) 2009; 23 Maes (10.1016/j.biopsych.2011.04.013_bib55) 1995; 244 Söderlund (10.1016/j.biopsych.2011.04.013_bib85) 2009; 14 Maes (10.1016/j.biopsych.2011.04.013_bib54) 1994; 89 Barak (10.1016/j.biopsych.2011.04.013_bib25) 1995; 6 Müller (10.1016/j.biopsych.2011.04.013_bib11) 2002; 159 Pae (10.1016/j.biopsych.2011.04.013_bib70) 2006; 6 Haack (10.1016/j.biopsych.2011.04.013_bib42) 1999; 33 el-Mallakh (10.1016/j.biopsych.2011.04.013_bib34) 1993; 17 Shepherd (10.1016/j.biopsych.2011.04.013_bib104) 1989; 15 Akhondzadeh (10.1016/j.biopsych.2011.04.013_bib9) 2007; 90 Schattner (10.1016/j.biopsych.2011.04.013_bib80) 1996; 9 Nunes (10.1016/j.biopsych.2011.04.013_bib8) 2006; 84 al-Janadi (10.1016/j.biopsych.2011.04.013_bib100) 1993; 13 Shintani (10.1016/j.biopsych.2011.04.013_bib82) 1991; 49 Müller (10.1016/j.biopsych.2011.04.013_bib12) 2010; 121 Ganguli (10.1016/j.biopsych.2011.04.013_bib102) 1997; 18 Preble (10.1016/j.biopsych.2011.04.013_bib71) 1985; 142 Kowalski (10.1016/j.biopsych.2011.04.013_bib19) 2001; 50 Zhang (10.1016/j.biopsych.2011.04.013_bib98) 2009; 204 Potvin (10.1016/j.biopsych.2011.04.013_bib5) 2008; 63 Maes (10.1016/j.biopsych.2011.04.013_bib56) 1995; 29 Nikkilä (10.1016/j.biopsych.2011.04.013_bib66) 1999; 156 Bresee (10.1016/j.biopsych.2011.04.013_bib28) 2009; 12 Kaminska (10.1016/j.biopsych.2011.04.013_bib44) 2001; 49 Rapaport (10.1016/j.biopsych.2011.04.013_bib74) 1994; 35 Schwarz (10.1016/j.biopsych.2011.04.013_bib15) 2001; 56 Becker (10.1016/j.biopsych.2011.04.013_bib27) 1990; 157 Kim (10.1016/j.biopsych.2011.04.013_bib49) 2004; 28 Singh (10.1016/j.biopsych.2011.04.013_bib83) 2009; 47 Müller (10.1016/j.biopsych.2011.04.013_bib63) 1997; 247 Rapaport (10.1016/j.biopsych.2011.04.013_bib76) 1997; 21 Manavalan (10.1016/j.biopsych.2011.04.013_bib101) 2010; 71 Maes (10.1016/j.biopsych.2011.04.013_bib60) 2002; 54 Smith (10.1016/j.biopsych.2011.04.013_bib14) 1995; 45 Sullivan (10.1016/j.biopsych.2011.04.013_bib18) 2003; 60 Ebrinç (10.1016/j.biopsych.2011.04.013_bib33) 2002; 30 Xu (10.1016/j.biopsych.2011.04.013_bib94) 1994; 164 Müller (10.1016/j.biopsych.2011.04.013_bib62) 1997; 12 Nikkilä (10.1016/j.biopsych.2011.04.013_bib67) 2002; 46 Zhang (10.1016/j.biopsych.2011.04.013_bib96) 2005; 30 Drexhage (10.1016/j.biopsych.2011.04.013_bib107) 2011; 24 Baker (10.1016/j.biopsych.2011.04.013_bib24) 1996; 20 Naudin (10.1016/j.biopsych.2011.04.013_bib64) 1996; 20 Sarandol (10.1016/j.biopsych.2011.04.013_bib79) 2007; 21 Dickinson (10.1016/j.biopsych.2011.04.013_bib1) 2008; 64 Rapaport (10.1016/j.biopsych.2011.04.013_bib77) 1997; 25 McAllister (10.1016/j.biopsych.2011.04.013_bib78) 1995; 152 Bechter (10.1016/j.biopsych.2011.04.013_bib26) 2010; 44 Sirota (10.1016/j.biopsych.2011.04.013_bib84) 2005; 134 Drexhage (10.1016/j.biopsych.2011.04.013_bib32) 2008; 102 Nimgaonkar (10.1016/j.biopsych.2011.04.013_bib68) 1995; 60 Schwarz (10.1016/j.biopsych.2011.04.013_bib81) 1998; 248 Heath (10.1016/j.biopsych.2011.04.013_bib4) 1967; 16 Lin (10.1016/j.biopsych.2011.04.013_bib52) 1998; 32 Wyatt (10.1016/j.biopsych.2011.04.013_bib105) 1991; 5 Rapaport (10.1016/j.biopsych.2011.04.013_bib72) 1989; 46 Hope (10.1016/j.biopsych.2011.04.013_bib43) 2009; 11 Yang (10.1016/j.biopsych.2011.04.013_bib91) 1994; 24 Rapaport (10.1016/j.biopsych.2011.04.013_bib73) 1993; 243 Laan (10.1016/j.biopsych.2011.04.013_bib10) 2010; 71 García-Miss Mdel (10.1016/j.biopsych.2011.04.013_bib40) 2010; 44 Kim (10.1016/j.biopsych.2011.04.013_bib46) 2000; 44 Zhang (10.1016/j.biopsych.2011.04.013_bib95) 2004; 65 Maes (10.1016/j.biopsych.2011.04.013_bib58) 1997; 26 Müller (10.1016/j.biopsych.2011.04.013_bib13) 2004; 254 Zhang (10.1016/j.biopsych.2011.04.013_bib97) 2008; 201 Naudin (10.1016/j.biopsych.2011.04.013_bib65) 1997; 26 Maes (10.1016/j.biopsych.2011.04.013_bib59) 2000; 10 van Kammen (10.1016/j.biopsych.2011.04.013_bib7) 1999; 87 9332905 - Eur Arch Psychiatry Clin Neurosci. 1997;247(4):228-33 19939410 - J Psychiatr Res. 2010 May;44(7):441-6 12476326 - Mol Psychiatry. 2002;7(10):1107-14 19839997 - Bipolar Disord. 2009 Nov;11(7):726-34 7772617 - Eur Arch Psychiatry Clin Neurosci. 1995;244(6):325-9 19132187 - Thromb Haemost. 2009 Jan;101(1):36-47 17715203 - J Psychopharmacol. 2007 Nov;21(8):857-63 19502081 - Cytokine. 2009 Jul;47(1):1-5 18838250 - Schizophr Res. 2008 Dec;106(2-3):369-70 2798648 - Psychol Med Monogr Suppl. 1989;15:1-46 19796773 - J Psychiatr Res. 2010 Apr;44(5):321-30 8067274 - Acta Psychiatr Scand. 1994 May;89(5):346-51 16530388 - Schizophr Res. 2006 May;84(1):180-2 18562404 - J Psychopharmacol. 2009 May;23(3):287-94 18486454 - Schizophr Res. 2008 Jul;102(1-3):352-5 19389469 - Brain Behav Immun. 2009 Oct;23(7):887-97 15886721 - Neuropsychopharmacology. 2005 Aug;30(8):1532-8 21255481 - Int J Neuropsychopharmacol. 2011 Jul;14(6):746-55 15291683 - J Clin Psychiatry. 2004 Jul;65(7):940-7 8981392 - Neuropsychopharmacology. 1997 Jan;16(1):83-7 12566931 - Neuropsychobiology. 2002;46(4):169-72 8863007 - Eur Arch Psychiatry Clin Neurosci. 1996;246(5):279-84 9247977 - Psychiatry Res. 1997 Jun 16;71(1):11-7 9477010 - Eur Arch Psychiatry Clin Neurosci. 1997;247(6):308-13 10553735 - Am J Psychiatry. 1999 Nov;156(11):1725-9 11545247 - Mediators Inflamm. 2001 Jun;10(3):109-15 19058794 - Biol Psychiatry. 2009 Mar 15;65(6):481-8 19407273 - Br J Psychiatry. 2009 May;194(5):434-8 19139851 - Psychopharmacology (Berl). 2009 May;204(1):177-84 14662550 - Arch Gen Psychiatry. 2003 Dec;60(12):1187-92 20570110 - Schizophr Res. 2010 Aug;121(1-3):118-24 8546160 - Am J Med Genet. 1995 Oct 9;60(5):448-51 18472089 - Biol Psychiatry. 2008 Nov 1;64(9):823-7 1697774 - Br J Psychiatry. 1990 Jul;157:136-8 9278953 - Prog Neuropsychopharmacol Biol Psychiatry. 1997 Jul;21(5):817-27 9323355 - Schizophr Res. 1997 Aug 29;26(2-3):227-33 9187011 - Schizophr Res. 1997 May 24;25(2):123-9 8102512 - Am J Psychiatry. 1993 Sep;150(9):1408-10 4163107 - Arch Gen Psychiatry. 1967 Jan;16(1):24-33 12799618 - Neuropsychopharmacology. 2003 Aug;28(8):1515-20 8475320 - Prog Neuropsychopharmacol Biol Psychiatry. 1993 May;17(3):383-91 7910974 - Psychiatry Res. 1994 Jan;51(1):1-10 19698539 - Eur Psychiatry. 1997;12(6):294-9 1684719 - Schizophr Res. 1991 Oct;5(3):201-2 10579546 - Psychiatry Res. 1999 Oct 11;87(2-3):129-36 8084939 - Psychol Med. 1994 May;24(2):449-55 18722671 - Psychiatry Res. 2008 Sep 30;160(3):256-62 8934562 - Exp Neurol. 1996 Dec;142(2):313-22 15546066 - Pharmacopsychiatry. 2004 Nov;37 Suppl 2:S141-7 19920835 - Mol Psychiatry. 2009 Dec;14(12):1069-71 9690329 - Schizophr Res. 1998 Jun 22;32(1):9-15 4163019 - Arch Gen Psychiatry. 1967 Jan;16(1):1-9 11439237 - Schizophr Res. 2001 Jul 1;50(3):169-75 17208413 - Schizophr Res. 2007 Feb;90(1-3):179-85 10227112 - Schizophr Res. 1999 May 4;37(1):97-106 20492850 - J Clin Psychiatry. 2010 May;71(5):520-7 11913333 - Int J Neurosci. 2001;111(1-2):11-9 18243335 - Psychiatry Res. 2008 Mar 15;158(2):206-16 18679053 - Neuroimmunomodulation. 2008;15(2):140-4 14623497 - Prostaglandins Leukot Essent Fatty Acids. 2003 Dec;69(6):429-36 18005941 - Biol Psychiatry. 2008 Apr 15;63(8):801-8 8399412 - Eur Arch Psychiatry Clin Neurosci. 1993;243(1):7-10 10504009 - J Psychiatr Res. 1999 Sep-Oct;33(5):407-18 10706993 - Eur Neuropsychopharmacol. 2000 Mar;10(2):119-24 12223256 - Schizophr Res. 2002 Oct 1;57(2-3):247-58 19390223 - Neuropsychobiology. 2009;59(2):123-9 2412455 - Am J Psychiatry. 1985 Oct;142(10):1184-6 19579286 - Psychiatry Clin Neurosci. 2009 Jun;63(3):257-65 8794510 - Schizophr Res. 1996 May;20(1-2):199-203 1865759 - Life Sci. 1991;49(9):661-4 11853116 - Prog Neuropsychopharmacol Biol Psychiatry. 2002 Jan;26(1):33-9 19735687 - Hum Immunol. 2010 Jan;71(1):50-7 11950553 - Schizophr Res. 2002 Apr 1;54(3):281-91 2784048 - Arch Gen Psychiatry. 1989 Mar;46(3):292 11814238 - Arch Immunol Ther Exp (Warsz). 2001;49(6):439-45 2784047 - Arch Gen Psychiatry. 1989 Mar;46(3):291-2 9323354 - Schizophr Res. 1997 Aug 29;26(2-3):221-5 18719893 - Psychopharmacology (Berl). 2008 Dec;201(3):383-9 8933282 - J Autoimmun. 1996 Oct;9(5):661-6 7872033 - Acta Psychiatr Scand. 1994 Nov;90(5):311-5 12042193 - Am J Psychiatry. 2002 Jun;159(6):1029-34 19366488 - Int J Neuropsychopharmacol. 2009 Jul;12(6):861-5 8827853 - Schizophr Res. 1996 Jul 5;20(3):269-73 8445045 - J Clin Immunol. 1993 Jan;13(1):58-67 12166349 - J Int Med Res. 2002 May-Jun;30(3):314-7 11339852 - Med Hypotheses. 2001 Apr;56(4):483-6 11163541 - Schizophr Res. 2001 Jan 15;47(1):13-25 4163018 - Arch Gen Psychiatry. 1967 Jan;16(1):10-23 7969854 - Neuropsychobiology. 1994;30(1):20-3 9928906 - Eur Arch Psychiatry Clin Neurosci. 1998;248(6):282-8 1571315 - Schizophr Res. 1992 Mar;6(3):237-41 10962218 - Schizophr Res. 2000 Sep 1;44(3):165-75 16504930 - Int Immunopharmacol. 2006 Apr;6(4):666-71 7653683 - Am J Psychiatry. 1995 Sep;152(9):1291-7 15840416 - Psychiatry Res. 2005 Apr 15;134(2):151-9 8998275 - Schizophr Res. 1996 Jul;21(1):39-50 8531836 - Med Hypotheses. 1995 Aug;45(2):135-41 8562579 - J Basic Clin Physiol Pharmacol. 1995;6(1):61-9 14991374 - Eur Arch Psychiatry Clin Neurosci. 2004 Feb;254(1):14-22 15610925 - Prog Neuropsychopharmacol Biol Psychiatry. 2004 Nov;28(7):1129-34 7666381 - J Psychiatr Res. 1995 Mar-Apr;29(2):141-52 7909714 - Br J Psychiatry. 1994 Feb;164(2):251-3 8043705 - Biol Psychiatry. 1994 May 15;35(10):767-71 |
| References_xml | – volume: 24 start-page: 449 year: 1994 end-page: 455 ident: bib91 article-title: An association between anti-hippocampal antibody concentration and lymphocyte production of IL-2 in patients with schizophrenia publication-title: Psychol Med – volume: 71 start-page: 520 year: 2010 end-page: 527 ident: bib10 article-title: Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: Results from a randomized, double-blind, placebo-controlled trial publication-title: J Clin Psychiatry – volume: 248 start-page: 282 year: 1998 end-page: 288 ident: bib81 article-title: Autoantibodies against 60-kDa heat shock protein in schizophrenia publication-title: Eur Arch Psychiatry Clin Neurosci – volume: 23 start-page: 287 year: 2009 end-page: 294 ident: bib22 article-title: Kynurenine pathway in psychosis: Evidence of increased tryptophan degradation publication-title: J Psychopharmacol – volume: 102 start-page: 352 year: 2008 end-page: 355 ident: bib32 article-title: Patients with schizophrenia show raised serum levels of the pro-inflammatory chemokine CCL2: Association with the metabolic syndrome in patients? publication-title: Schizophr Res – volume: 16 start-page: 10 year: 1967 end-page: 23 ident: bib3 article-title: Schizophrenia as an immunologic disorder. II. Effects of serum protein fractions on brain function publication-title: Arch Gen Psychiatry – volume: 254 start-page: 14 year: 2004 end-page: 22 ident: bib13 article-title: COX-2 inhibition as a treatment approach in schizophrenia: Immunological considerations and clinical effects of celecoxib add-on therapy publication-title: Eur Arch Psychiatry Clin Neurosci – volume: 16 start-page: 24 year: 1967 end-page: 33 ident: bib4 article-title: Schizophrenia as an immunologic disorder. 3. Effects of antimonkey and antihuman brain antibody on brain function publication-title: Arch Gen Psychiatry – volume: 65 start-page: 481 year: 2009 end-page: 488 ident: bib86 article-title: The interaction of nuclear factor-kappa B and cytokines is associated with schizophrenia publication-title: Biol Psychiatry – volume: 10 start-page: 109 year: 2001 end-page: 115 ident: bib35 article-title: Serum IL-1beta, sIL-2R, IL-6, IL-8 and TNF-alpha in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment publication-title: Mediators Inflamm – volume: 142 start-page: 1184 year: 1985 end-page: 1186 ident: bib71 article-title: Serum interferon in patients with psychosis publication-title: Am J Psychiatry – volume: 65 start-page: 940 year: 2004 end-page: 947 ident: bib95 article-title: Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: Relationship to outcome in schizophrenia publication-title: J Clin Psychiatry – volume: 246 start-page: 279 year: 1996 end-page: 284 ident: bib20 article-title: Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients publication-title: Eur Arch Psychiatry Clin Neurosci – volume: 247 start-page: 308 year: 1997 end-page: 313 ident: bib63 article-title: Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia publication-title: Eur Arch Psychiatry Clin Neurosci – volume: 194 start-page: 434 year: 2009 end-page: 438 ident: bib36 article-title: Metabolic profile of antipsychotic-naïve patients with nonaffective psychosis publication-title: Br J Psychiatry – volume: 37 start-page: 97 year: 1999 end-page: 106 ident: bib23 article-title: Serum levels of soluble IL-2 receptor alpha, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration publication-title: Schizophr Res – volume: 26 start-page: 33 year: 2002 end-page: 39 ident: bib29 article-title: Cytokine profiles in schizophrenic patients treated with risperidone: A 3-month follow-up study publication-title: Prog Neuropsychopharmacol Biol Psychiatry – volume: 44 start-page: 321 year: 2010 end-page: 330 ident: bib26 article-title: Cerebrospinal fluid analysis in affective and schizophrenic spectrum disorders: Identification of subgroups with immune responses and blood-CSF barrier dysfunction publication-title: J Psychiatr Res – volume: 63 start-page: 257 year: 2009 end-page: 265 ident: bib16 article-title: Cytokines and schizophrenia: Microglia hypothesis of schizophrenia publication-title: Psychiatry Clin Neurosci – volume: 15 start-page: 1 year: 1989 end-page: 46 ident: bib104 article-title: The natural history of schizophrenia: A five-year follow-up study of outcome and prediction in a representative sample of schizophrenics publication-title: Psychol Med.Monogr Suppl – volume: 14 start-page: 1069 year: 2009 end-page: 1071 ident: bib85 article-title: Activation of brain interleukin-1beta in schizophrenia publication-title: Mol Psychiatry – volume: 248 start-page: 282 year: 1998 end-page: 288 ident: bib21 article-title: Autoantibodies against 60-kDa heat shock protein in schizophrenia publication-title: Eur Arch Psychiatry Clin Neurosci – volume: 60 start-page: 448 year: 1995 end-page: 451 ident: bib68 article-title: Association study of schizophrenia and the IL-2 receptor beta chain gene publication-title: Am J Med Genet – volume: 21 start-page: 39 year: 1996 end-page: 50 ident: bib57 article-title: Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: Effects of antipsychotic drugs publication-title: Schizophr Res – volume: 46 start-page: 291 year: 1989 end-page: 292 ident: bib72 article-title: Elevated levels of soluble interleukin 2 receptors in schizophrenia publication-title: Arch Gen Psychiatry – volume: 150 start-page: 1408 year: 1993 end-page: 1410 ident: bib51 article-title: Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients publication-title: Am J Psychiatry – volume: 87 start-page: 129 year: 1999 end-page: 136 ident: bib7 article-title: Elevated interleukin-6 in schizophrenia publication-title: Psychiatry Res – volume: 71 start-page: 11 year: 1997 end-page: 17 ident: bib61 article-title: Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: Effects of clozapine treatment publication-title: Psychiatry Res – volume: 46 start-page: 169 year: 2002 end-page: 172 ident: bib67 article-title: Neopterin and macrophage inflammatory protein-1alpha in the cerebrospinal fluid of schizophrenic patients: No evidence of intrathecal inflammation publication-title: Neuropsychobiology – volume: 152 start-page: 1291 year: 1995 end-page: 1297 ident: bib78 article-title: Increases in CSF levels of interleukin-2 in schizophrenia: Effects of recurrence of psychosis and medication status publication-title: Am J Psychiatry – volume: 69 start-page: 429 year: 2003 end-page: 436 ident: bib92 article-title: Membrane polyunsaturated fatty acids and CSF cytokines in patients with schizophrenia publication-title: Prostaglandins Leukot Essent Fatty Acids – volume: 60 start-page: 1187 year: 2003 end-page: 1192 ident: bib18 article-title: Schizophrenia as a complex trait: Evidence from a meta-analysis of twin studies publication-title: Arch Gen Psychiatry – volume: 111 start-page: 11 year: 2001 end-page: 19 ident: bib47 article-title: Effect of risperidone on serum cytokines publication-title: Int J Neurosci – volume: 13 start-page: 58 year: 1993 end-page: 67 ident: bib100 article-title: Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis, and other rheumatic diseases publication-title: J Clin Immunol – volume: 47 start-page: 13 year: 2001 end-page: 25 ident: bib87 article-title: Cytokine serum levels, autologous mixed lymphocyte reaction and surface marker analysis in never medicated and chronically medicated schizophrenic patients publication-title: Schizophr Res – volume: 24 start-page: 1 year: 2011 end-page: 10 ident: bib107 article-title: An activated set point of T-cell and monocyte inflammatory networks in recent-onset schizophrenia patients involves both pro- and anti-inflammatory forces publication-title: Int J Neuropsychopharmacol – volume: 160 start-page: 256 year: 2008 end-page: 262 ident: bib69 article-title: Increased tumor necrosis factor-alpha concentrations with interleukin-4 concentrations in exacerbations of schizophrenia publication-title: Psychiatry Res – volume: 28 start-page: 1515 year: 2003 end-page: 1520 ident: bib6 article-title: Elevated interleukin-6 in the cerebrospinal fluid of a previously delineated schizophrenia subtype publication-title: Neuropsychopharmacology – volume: 121 start-page: 118 year: 2010 end-page: 124 ident: bib12 article-title: Celecoxib treatment in an early stage of schizophrenia: Results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment publication-title: Schizophr Res – volume: 63 start-page: 801 year: 2008 end-page: 808 ident: bib5 article-title: Inflammatory cytokine alterations in schizophrenia: A systematic quantitative review publication-title: Biol Psychiatry – volume: 17 start-page: 206 year: 2003 end-page: 208 ident: bib53 article-title: Interleukin level in CSF of patients with first episode schizophrenia publication-title: Chinese Mental Health Journal – volume: 158 start-page: 206 year: 2008 end-page: 216 ident: bib31 article-title: Interleukin-12 plasma levels in drug-naïve patients with a first episode of psychosis: Effects of antipsychotic drugs publication-title: Psychiatry Res – volume: 106 start-page: 369 year: 2008 end-page: 370 ident: bib90 article-title: Altered interleukin-3 serum levels in drug-naïve and neuroleptic-treated schizophrenic patients publication-title: Schizophr Res – volume: 16 start-page: 83 year: 1997 end-page: 87 ident: bib89 article-title: Transforming growth factors beta 1 and beta 2 in the cerebrospinal fluid of chronic schizophrenic patients publication-title: Neuropsychopharmacology – volume: 45 start-page: 135 year: 1995 end-page: 141 ident: bib14 article-title: The macrophage-T-lymphocyte theory of schizophrenia: Additional evidence publication-title: Med Hypotheses – volume: 17 start-page: 383 year: 1993 end-page: 391 ident: bib34 article-title: Interleukin-1 alpha and interleukin-2 in cerebrospinal fluid of schizophrenic subjects publication-title: Prog Neuropsychopharmacol Biol Psychiatry – volume: 8 start-page: 275 year: 2000 end-page: 292 ident: bib99 article-title: Fixed effects vs. random effects meta-analysis models: Implications for cumulative research knowledge publication-title: Int J Sel Assess – volume: 164 start-page: 251 year: 1994 end-page: 253 ident: bib94 article-title: Changes of plasma concentrations of interleukin-1 alpha and interleukin-6 with neuroleptic treatment for schizophrenia publication-title: Br J Psychiatry – volume: 204 start-page: 177 year: 2009 end-page: 184 ident: bib98 article-title: Superoxide dismutase and cytokines in chronic patients with schizophrenia: Association with psychopathology and response to antipsychotics publication-title: Psychopharmacology (Berl) – volume: 90 start-page: 179 year: 2007 end-page: 185 ident: bib9 article-title: Celecoxib as adjunctive therapy in schizophrenia: A double-blind, randomized and placebo-controlled trial publication-title: Schizophr Res – volume: 37 start-page: S141 year: 2004 end-page: S147 ident: bib103 article-title: Mechanisms of relapse prevention in schizophrenia publication-title: Pharmacopsychiatry – volume: 18 start-page: 35 year: 1997 end-page: 43 ident: bib102 article-title: Clinical and immunological characteristics of a subgroup of patients suffering from schizophrenia publication-title: Immunological Alterations in Psychiatric Diseases – volume: 159 start-page: 1029 year: 2002 end-page: 1034 ident: bib11 article-title: Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia publication-title: Am J Psychiatry – volume: 10 start-page: 119 year: 2000 end-page: 124 ident: bib59 article-title: Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics publication-title: Eur Neuropsychopharmacol – volume: 12 start-page: 294 year: 1997 end-page: 299 ident: bib62 article-title: Soluble IL-6 receptors in the serum and cerebrospinal fluid of paranoid schizophrenic patients publication-title: Eur Psychiatry – volume: 6 start-page: 237 year: 1992 end-page: 241 ident: bib41 article-title: Abnormalities in serum concentrations of interleukin-2, interferon-alpha and interferon-gamma in schizophrenia not detected publication-title: Schizophr Res – volume: 7 start-page: 1107 year: 2002 end-page: 1114 ident: bib48 article-title: The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: Effects of psychotropic drugs publication-title: Mol Psychiatry – volume: 84 start-page: 180 year: 2006 end-page: 182 ident: bib8 article-title: An autoimmune or an inflammatory process in patients with schizophrenia, schizoaffective disorder, and in their biological relatives publication-title: Schizophr Res – volume: 11 start-page: 726 year: 2009 end-page: 734 ident: bib43 article-title: Similar immune profile in bipolar disorder and schizophrenia: Selective increase in soluble tumor necrosis factor receptor I and von Willebrand factor publication-title: Bipolar Disord – volume: 28 start-page: 1129 year: 2004 end-page: 1134 ident: bib49 article-title: Th1, Th2 and Th3 cytokine alteration in schizophrenia publication-title: Prog Neuropsychopharmacol Biol Psychiatry – volume: 5 start-page: 201 year: 1991 end-page: 202 ident: bib105 article-title: Early intervention with neuroleptics may decrease the long-term morbidity of schizophrenia publication-title: Schizophr Res – volume: 54 start-page: 281 year: 2002 end-page: 291 ident: bib60 article-title: Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor publication-title: Schizophr Res – volume: 21 start-page: 857 year: 2007 end-page: 863 ident: bib79 article-title: Coronary artery disease risk factors in patients with schizophrenia: Effects of short term antipsychotic treatment publication-title: J Psychopharmacol – volume: 12 start-page: 861 year: 2009 end-page: 865 ident: bib28 article-title: Persistently increased serum soluble interleukin-2 receptors in continuously ill patients with schizophrenia publication-title: Int J Neuropsychopharmacol – volume: 71 start-page: 50 year: 2010 end-page: 57 ident: bib101 article-title: Serum cytokine elevations in celiac disease: Association with disease presentation publication-title: Hum Immunol – volume: 20 start-page: 199 year: 1996 end-page: 203 ident: bib24 article-title: Serum cytokine concentrations in patients with schizophrenia publication-title: Schizophr Res – volume: 64 start-page: 823 year: 2008 end-page: 827 ident: bib1 article-title: General and specific cognitive deficits in schizophrenia: Goliath defeats David? publication-title: Biol Psychiatry – volume: 6 start-page: 61 year: 1995 end-page: 69 ident: bib25 article-title: Changes in interleukin-1 beta and soluble interleukin-2 receptor levels in CSF and serum of schizophrenic patients publication-title: J Basic Clin Physiol Pharmacol – volume: 15 start-page: 140 year: 2008 end-page: 144 ident: bib30 article-title: Increased serum levels of inflammatory markers in chronic institutionalized patients with schizophrenia publication-title: Neuroimmunomodulation – volume: 49 start-page: 661 year: 1991 end-page: 664 ident: bib82 article-title: Serum interleukin-6 in schizophrenic patients publication-title: Life Sci – volume: 16 start-page: 1 year: 1967 end-page: 9 ident: bib2 article-title: Schizophrenia as an immunologic disorder. I. Demonstration of antibrain globulins by fluorescent antibody techniques publication-title: Arch Gen Psychiatry – volume: 29 start-page: 141 year: 1995 end-page: 152 ident: bib56 article-title: Interleukin-2 and interleukin-6 in schizophrenia and mania: Effects of neuroleptics and mood stabilizers publication-title: J Psychiatr Res – volume: 90 start-page: 311 year: 1994 end-page: 315 ident: bib75 article-title: Serum-soluble interleukin-2 receptors in neuroleptic-naive schizophrenic subjects and in medicated schizophrenic subjects with and without tardive dyskinesia publication-title: Acta Psychiatr Scand – volume: 23 start-page: 887 year: 2009 end-page: 897 ident: bib17 article-title: To assess, to control, to exclude: Effects of biobehavioral factors on circulating inflammatory markers publication-title: Brain Behav Immun – volume: 101 start-page: 36 year: 2009 end-page: 47 ident: bib106 article-title: Compensatory anti-inflammatory response syndrome publication-title: Thromb Haemost – volume: 26 start-page: 221 year: 1997 end-page: 225 ident: bib58 article-title: In vivo immunomodulatory effects of clozapine in schizophrenia publication-title: Schizophr Res – volume: 156 start-page: 1725 year: 1999 end-page: 1729 ident: bib66 article-title: Accumulation of macrophages in the CSF of schizophrenic patients during acute psychotic episodes publication-title: Am J Psychiatry – volume: 57 start-page: 247 year: 2002 end-page: 258 ident: bib93 article-title: Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: Association with psychopathology publication-title: Schizophr Res – volume: 201 start-page: 383 year: 2008 end-page: 389 ident: bib97 article-title: Lower serum cytokine levels in smokers than nonsmokers with chronic schizophrenia on long-term treatment with antipsychotics publication-title: Psychopharmacology (Berl) – volume: 89 start-page: 346 year: 1994 end-page: 351 ident: bib54 article-title: Immune-inflammatory markers in schizophrenia: Comparison to normal controls and effects of clozapine publication-title: Acta Psychiatr Scand – volume: 33 start-page: 407 year: 1999 end-page: 418 ident: bib42 article-title: Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: Effects of confounding factors and diagnosis publication-title: J Psychiatr Res – volume: 243 start-page: 7 year: 1993 end-page: 10 ident: bib73 article-title: Increased serum soluble interleukin-2 receptors in schizophrenic monozygotic twins publication-title: Eur Arch Psychiatry Clin Neurosci – volume: 32 start-page: 9 year: 1998 end-page: 15 ident: bib52 article-title: The inflammatory response system in treatment-resistant schizophrenia: Increased serum interleukin-6 publication-title: Schizophr Res – volume: 56 start-page: 483 year: 2001 end-page: 486 ident: bib15 article-title: The Th2-hypothesis of schizophrenia: A strategy to identify a subgroup of schizophrenia caused by immune mechanisms publication-title: Med Hypotheses – volume: 47 start-page: 1 year: 2009 end-page: 5 ident: bib83 article-title: Decreased serum levels of interleukin-2 and interleukin-6 in Indian Bengalee schizophrenic patients publication-title: Cytokine – volume: 157 start-page: 136 year: 1990 end-page: 138 ident: bib27 article-title: Serum interferon in first psychotic attack publication-title: Br J Psychiatry – volume: 25 start-page: 123 year: 1997 end-page: 129 ident: bib77 article-title: CSF IL-1 and IL-2 in medicated schizophrenic patients and normal volunteers publication-title: Schizophr Res – volume: 59 start-page: 123 year: 2009 end-page: 129 ident: bib50 article-title: Cytokine changes and tryptophan metabolites in medication-naïve and medication-free schizophrenic patients publication-title: Neuropsychobiology – volume: 26 start-page: 27 year: 1997 end-page: 233 ident: bib65 article-title: A differential role for interleukin-6 and tumor necrosis factor-alpha in schizophrenia? publication-title: Schizophr Res – volume: 244 start-page: 325 year: 1995 end-page: 329 ident: bib55 article-title: Plasma-soluble interleukin-2 and transferrin receptor in schizophrenia and major depression publication-title: Eur Arch Psychiatry Clin Neurosci – volume: 9 start-page: 661 year: 1996 end-page: 666 ident: bib80 article-title: No evidence for autoimmunity in schizophrenia publication-title: J Autoimmun – volume: 134 start-page: 151 year: 2005 end-page: 159 ident: bib84 article-title: Effect of neuroleptic administration on serum levels of soluble IL-2 receptor-alpha and IL-1 receptor antagonist in schizophrenic patients publication-title: Psychiatry Res – volume: 49 start-page: 439 year: 2001 end-page: 445 ident: bib44 article-title: Investigation of serum cytokine levels and cytokine production in whole blood cultures of paranoid schizophrenic patients publication-title: Arch Immunol. Ther Exp (Warsz) – volume: 44 start-page: 165 year: 2000 end-page: 175 ident: bib46 article-title: Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics publication-title: Schizophr Res – volume: 30 start-page: 314 year: 2002 end-page: 317 ident: bib33 article-title: Serum interleukin 1 alpha and interleukin 2 levels in patients with schizophrenia publication-title: J Int Med Res – volume: 44 start-page: 441 year: 2010 end-page: 446 ident: bib40 article-title: Folate, homocysteine, interleukin-6, and tumor necrosis factor alfa levels, but not the methylenetetrahydrofolate reductase C677T polymorphism, are risk factors for schizophrenia publication-title: J Psychiatr Res – volume: 21 start-page: 817 year: 1997 end-page: 827 ident: bib76 article-title: An association between increased serum-soluble interleukin-2 receptors and a disturbance in muscle force in schizophrenic patients publication-title: Prog Neuropsychopharmacol Biol Psychiatry – volume: 6 start-page: 666 year: 2006 end-page: 671 ident: bib70 article-title: Antipsychotic treatment may alter T-helper (TH) 2 arm cytokines publication-title: Int Immunopharmacol – volume: 50 start-page: 169 year: 2001 end-page: 175 ident: bib19 article-title: Neuroleptics normalize increased release of interleukin-1 beta and tumor necrosis factor-alpha from monocytes in schizophrenia publication-title: Schizophr Res – volume: 247 start-page: 228 year: 1997 end-page: 233 ident: bib37 article-title: Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: Comparison between the acute state and after remission publication-title: Eur Arch Psychiatry Clin Neurosci – volume: 30 start-page: 20 year: 1994 end-page: 23 ident: bib45 article-title: Plasma and cerebrospinal fluid interleukin-1 beta and interleukin-6 in hospitalized schizophrenic patients publication-title: Neuropsychobiology – volume: 51 start-page: 1 year: 1994 end-page: 10 ident: bib39 article-title: Serum interleukin-6 concentration in schizophrenia: Elevation associated with duration of illness publication-title: Psychiatry Res – volume: 20 start-page: 269 year: 1996 end-page: 273 ident: bib64 article-title: Elevated circulating levels of IL-6 in schizophrenia publication-title: Schizophr Res – volume: 35 start-page: 767 year: 1994 end-page: 771 ident: bib74 article-title: Increased serum soluble interleukin-2 receptors in Caucasian and Korean schizophrenic patients publication-title: Biol Psychiatry – volume: 46 start-page: 292 year: 1989 ident: bib38 article-title: Increased serum interleukin 2 receptor concentration in schizophrenic and brain-damaged subjects publication-title: Arch Gen Psychiatry – volume: 142 start-page: 313 year: 1996 end-page: 322 ident: bib88 article-title: TGFbeta1 and TGFbeta2 concentrations are elevated in Parkinson's disease in ventricular cerebrospinal fluid publication-title: Exp Neurol – volume: 30 start-page: 1532 year: 2005 end-page: 1538 ident: bib96 article-title: Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: Association with psychopathology and response to antipsychotics publication-title: Neuropsychopharmacology – volume: 24 start-page: 1 year: 2011 ident: 10.1016/j.biopsych.2011.04.013_bib107 article-title: An activated set point of T-cell and monocyte inflammatory networks in recent-onset schizophrenia patients involves both pro- and anti-inflammatory forces publication-title: Int J Neuropsychopharmacol – volume: 12 start-page: 861 year: 2009 ident: 10.1016/j.biopsych.2011.04.013_bib28 article-title: Persistently increased serum soluble interleukin-2 receptors in continuously ill patients with schizophrenia publication-title: Int J Neuropsychopharmacol doi: 10.1017/S1461145709000315 – volume: 157 start-page: 136 year: 1990 ident: 10.1016/j.biopsych.2011.04.013_bib27 article-title: Serum interferon in first psychotic attack publication-title: Br J Psychiatry doi: 10.1192/bjp.157.1.136 – volume: 8 start-page: 275 year: 2000 ident: 10.1016/j.biopsych.2011.04.013_bib99 article-title: Fixed effects vs. random effects meta-analysis models: Implications for cumulative research knowledge publication-title: Int J Sel Assess doi: 10.1111/1468-2389.00156 – volume: 17 start-page: 206 year: 2003 ident: 10.1016/j.biopsych.2011.04.013_bib53 article-title: Interleukin level in CSF of patients with first episode schizophrenia publication-title: Chinese Mental Health Journal – volume: 47 start-page: 1 year: 2009 ident: 10.1016/j.biopsych.2011.04.013_bib83 article-title: Decreased serum levels of interleukin-2 and interleukin-6 in Indian Bengalee schizophrenic patients publication-title: Cytokine doi: 10.1016/j.cyto.2009.05.005 – volume: 26 start-page: 221 year: 1997 ident: 10.1016/j.biopsych.2011.04.013_bib58 article-title: In vivo immunomodulatory effects of clozapine in schizophrenia publication-title: Schizophr Res doi: 10.1016/S0920-9964(97)00057-1 – volume: 244 start-page: 325 year: 1995 ident: 10.1016/j.biopsych.2011.04.013_bib55 article-title: Plasma-soluble interleukin-2 and transferrin receptor in schizophrenia and major depression publication-title: Eur Arch Psychiatry Clin Neurosci doi: 10.1007/BF02190412 – volume: 15 start-page: 1 year: 1989 ident: 10.1016/j.biopsych.2011.04.013_bib104 article-title: The natural history of schizophrenia: A five-year follow-up study of outcome and prediction in a representative sample of schizophrenics publication-title: Psychol Med.Monogr Suppl doi: 10.1017/S026418010000059X – volume: 71 start-page: 11 year: 1997 ident: 10.1016/j.biopsych.2011.04.013_bib61 article-title: Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: Effects of clozapine treatment publication-title: Psychiatry Res doi: 10.1016/S0165-1781(97)00036-X – volume: 47 start-page: 13 year: 2001 ident: 10.1016/j.biopsych.2011.04.013_bib87 article-title: Cytokine serum levels, autologous mixed lymphocyte reaction and surface marker analysis in never medicated and chronically medicated schizophrenic patients publication-title: Schizophr Res doi: 10.1016/S0920-9964(00)00007-4 – volume: 16 start-page: 1 year: 1967 ident: 10.1016/j.biopsych.2011.04.013_bib2 article-title: Schizophrenia as an immunologic disorder. I. Demonstration of antibrain globulins by fluorescent antibody techniques publication-title: Arch Gen Psychiatry doi: 10.1001/archpsyc.1967.01730190003001 – volume: 21 start-page: 817 year: 1997 ident: 10.1016/j.biopsych.2011.04.013_bib76 article-title: An association between increased serum-soluble interleukin-2 receptors and a disturbance in muscle force in schizophrenic patients publication-title: Prog Neuropsychopharmacol Biol Psychiatry doi: 10.1016/S0278-5846(97)00082-1 – volume: 59 start-page: 123 year: 2009 ident: 10.1016/j.biopsych.2011.04.013_bib50 article-title: Cytokine changes and tryptophan metabolites in medication-naïve and medication-free schizophrenic patients publication-title: Neuropsychobiology doi: 10.1159/000213565 – volume: 164 start-page: 251 year: 1994 ident: 10.1016/j.biopsych.2011.04.013_bib94 article-title: Changes of plasma concentrations of interleukin-1 alpha and interleukin-6 with neuroleptic treatment for schizophrenia publication-title: Br J Psychiatry doi: 10.1192/bjp.164.2.251 – volume: 56 start-page: 483 year: 2001 ident: 10.1016/j.biopsych.2011.04.013_bib15 article-title: The Th2-hypothesis of schizophrenia: A strategy to identify a subgroup of schizophrenia caused by immune mechanisms publication-title: Med Hypotheses doi: 10.1054/mehy.2000.1203 – volume: 33 start-page: 407 year: 1999 ident: 10.1016/j.biopsych.2011.04.013_bib42 article-title: Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: Effects of confounding factors and diagnosis publication-title: J Psychiatr Res doi: 10.1016/S0022-3956(99)00021-7 – volume: 69 start-page: 429 year: 2003 ident: 10.1016/j.biopsych.2011.04.013_bib92 article-title: Membrane polyunsaturated fatty acids and CSF cytokines in patients with schizophrenia publication-title: Prostaglandins Leukot Essent Fatty Acids doi: 10.1016/j.plefa.2003.08.015 – volume: 16 start-page: 24 year: 1967 ident: 10.1016/j.biopsych.2011.04.013_bib4 article-title: Schizophrenia as an immunologic disorder. 3. Effects of antimonkey and antihuman brain antibody on brain function publication-title: Arch Gen Psychiatry doi: 10.1001/archpsyc.1967.01730190026003 – volume: 44 start-page: 441 year: 2010 ident: 10.1016/j.biopsych.2011.04.013_bib40 article-title: Folate, homocysteine, interleukin-6, and tumor necrosis factor alfa levels, but not the methylenetetrahydrofolate reductase C677T polymorphism, are risk factors for schizophrenia publication-title: J Psychiatr Res doi: 10.1016/j.jpsychires.2009.10.011 – volume: 6 start-page: 237 year: 1992 ident: 10.1016/j.biopsych.2011.04.013_bib41 article-title: Abnormalities in serum concentrations of interleukin-2, interferon-alpha and interferon-gamma in schizophrenia not detected publication-title: Schizophr Res doi: 10.1016/0920-9964(92)90006-Q – volume: 60 start-page: 448 year: 1995 ident: 10.1016/j.biopsych.2011.04.013_bib68 article-title: Association study of schizophrenia and the IL-2 receptor beta chain gene publication-title: Am J Med Genet doi: 10.1002/ajmg.1320600517 – volume: 6 start-page: 666 year: 2006 ident: 10.1016/j.biopsych.2011.04.013_bib70 article-title: Antipsychotic treatment may alter T-helper (TH) 2 arm cytokines publication-title: Int Immunopharmacol doi: 10.1016/j.intimp.2005.10.004 – volume: 21 start-page: 857 year: 2007 ident: 10.1016/j.biopsych.2011.04.013_bib79 article-title: Coronary artery disease risk factors in patients with schizophrenia: Effects of short term antipsychotic treatment publication-title: J Psychopharmacol doi: 10.1177/0269881107077609 – volume: 18 start-page: 35 year: 1997 ident: 10.1016/j.biopsych.2011.04.013_bib102 article-title: Clinical and immunological characteristics of a subgroup of patients suffering from schizophrenia – volume: 247 start-page: 228 year: 1997 ident: 10.1016/j.biopsych.2011.04.013_bib37 article-title: Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: Comparison between the acute state and after remission publication-title: Eur Arch Psychiatry Clin Neurosci doi: 10.1007/BF02900219 – volume: 46 start-page: 169 year: 2002 ident: 10.1016/j.biopsych.2011.04.013_bib67 article-title: Neopterin and macrophage inflammatory protein-1alpha in the cerebrospinal fluid of schizophrenic patients: No evidence of intrathecal inflammation publication-title: Neuropsychobiology doi: 10.1159/000067805 – volume: 57 start-page: 247 year: 2002 ident: 10.1016/j.biopsych.2011.04.013_bib93 article-title: Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: Association with psychopathology publication-title: Schizophr Res doi: 10.1016/S0920-9964(01)00296-1 – volume: 5 start-page: 201 year: 1991 ident: 10.1016/j.biopsych.2011.04.013_bib105 article-title: Early intervention with neuroleptics may decrease the long-term morbidity of schizophrenia publication-title: Schizophr Res doi: 10.1016/0920-9964(91)90073-Z – volume: 134 start-page: 151 year: 2005 ident: 10.1016/j.biopsych.2011.04.013_bib84 article-title: Effect of neuroleptic administration on serum levels of soluble IL-2 receptor-alpha and IL-1 receptor antagonist in schizophrenic patients publication-title: Psychiatry Res doi: 10.1016/j.psychres.2004.04.012 – volume: 14 start-page: 1069 year: 2009 ident: 10.1016/j.biopsych.2011.04.013_bib85 article-title: Activation of brain interleukin-1beta in schizophrenia publication-title: Mol Psychiatry doi: 10.1038/mp.2009.52 – volume: 90 start-page: 311 year: 1994 ident: 10.1016/j.biopsych.2011.04.013_bib75 article-title: Serum-soluble interleukin-2 receptors in neuroleptic-naive schizophrenic subjects and in medicated schizophrenic subjects with and without tardive dyskinesia publication-title: Acta Psychiatr Scand doi: 10.1111/j.1600-0447.1994.tb01599.x – volume: 63 start-page: 801 year: 2008 ident: 10.1016/j.biopsych.2011.04.013_bib5 article-title: Inflammatory cytokine alterations in schizophrenia: A systematic quantitative review publication-title: Biol Psychiatry doi: 10.1016/j.biopsych.2007.09.024 – volume: 158 start-page: 206 year: 2008 ident: 10.1016/j.biopsych.2011.04.013_bib31 article-title: Interleukin-12 plasma levels in drug-naïve patients with a first episode of psychosis: Effects of antipsychotic drugs publication-title: Psychiatry Res doi: 10.1016/j.psychres.2006.08.005 – volume: 25 start-page: 123 year: 1997 ident: 10.1016/j.biopsych.2011.04.013_bib77 article-title: CSF IL-1 and IL-2 in medicated schizophrenic patients and normal volunteers publication-title: Schizophr Res doi: 10.1016/S0920-9964(97)00008-X – volume: 60 start-page: 1187 year: 2003 ident: 10.1016/j.biopsych.2011.04.013_bib18 article-title: Schizophrenia as a complex trait: Evidence from a meta-analysis of twin studies publication-title: Arch Gen Psychiatry doi: 10.1001/archpsyc.60.12.1187 – volume: 10 start-page: 119 year: 2000 ident: 10.1016/j.biopsych.2011.04.013_bib59 article-title: Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics publication-title: Eur Neuropsychopharmacol doi: 10.1016/S0924-977X(99)00062-0 – volume: 26 start-page: 27 year: 1997 ident: 10.1016/j.biopsych.2011.04.013_bib65 article-title: A differential role for interleukin-6 and tumor necrosis factor-alpha in schizophrenia? publication-title: Schizophr Res doi: 10.1016/S0920-9964(97)00059-5 – volume: 32 start-page: 9 year: 1998 ident: 10.1016/j.biopsych.2011.04.013_bib52 article-title: The inflammatory response system in treatment-resistant schizophrenia: Increased serum interleukin-6 publication-title: Schizophr Res doi: 10.1016/S0920-9964(98)00034-6 – volume: 160 start-page: 256 year: 2008 ident: 10.1016/j.biopsych.2011.04.013_bib69 article-title: Increased tumor necrosis factor-alpha concentrations with interleukin-4 concentrations in exacerbations of schizophrenia publication-title: Psychiatry Res doi: 10.1016/j.psychres.2007.11.014 – volume: 121 start-page: 118 year: 2010 ident: 10.1016/j.biopsych.2011.04.013_bib12 article-title: Celecoxib treatment in an early stage of schizophrenia: Results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment publication-title: Schizophr Res doi: 10.1016/j.schres.2010.04.015 – volume: 7 start-page: 1107 year: 2002 ident: 10.1016/j.biopsych.2011.04.013_bib48 article-title: The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: Effects of psychotropic drugs publication-title: Mol Psychiatry doi: 10.1038/sj.mp.4001084 – volume: 21 start-page: 39 year: 1996 ident: 10.1016/j.biopsych.2011.04.013_bib57 article-title: Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: Effects of antipsychotic drugs publication-title: Schizophr Res doi: 10.1016/0920-9964(96)00029-1 – volume: 156 start-page: 1725 year: 1999 ident: 10.1016/j.biopsych.2011.04.013_bib66 article-title: Accumulation of macrophages in the CSF of schizophrenic patients during acute psychotic episodes publication-title: Am J Psychiatry doi: 10.1176/ajp.156.11.1725 – volume: 28 start-page: 1129 year: 2004 ident: 10.1016/j.biopsych.2011.04.013_bib49 article-title: Th1, Th2 and Th3 cytokine alteration in schizophrenia publication-title: Prog Neuropsychopharmacol Biol Psychiatry doi: 10.1016/j.pnpbp.2004.05.047 – volume: 71 start-page: 50 year: 2010 ident: 10.1016/j.biopsych.2011.04.013_bib101 article-title: Serum cytokine elevations in celiac disease: Association with disease presentation publication-title: Hum Immunol doi: 10.1016/j.humimm.2009.09.351 – volume: 248 start-page: 282 year: 1998 ident: 10.1016/j.biopsych.2011.04.013_bib21 article-title: Autoantibodies against 60-kDa heat shock protein in schizophrenia publication-title: Eur Arch Psychiatry Clin Neurosci doi: 10.1007/s004060050051 – volume: 54 start-page: 281 year: 2002 ident: 10.1016/j.biopsych.2011.04.013_bib60 article-title: Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor publication-title: Schizophr Res doi: 10.1016/S0920-9964(00)00094-3 – volume: 13 start-page: 58 year: 1993 ident: 10.1016/j.biopsych.2011.04.013_bib100 article-title: Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis, and other rheumatic diseases publication-title: J Clin Immunol doi: 10.1007/BF00920636 – volume: 65 start-page: 481 year: 2009 ident: 10.1016/j.biopsych.2011.04.013_bib86 article-title: The interaction of nuclear factor-kappa B and cytokines is associated with schizophrenia publication-title: Biol Psychiatry doi: 10.1016/j.biopsych.2008.10.018 – volume: 10 start-page: 109 year: 2001 ident: 10.1016/j.biopsych.2011.04.013_bib35 article-title: Serum IL-1beta, sIL-2R, IL-6, IL-8 and TNF-alpha in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment publication-title: Mediators Inflamm doi: 10.1080/09629350123895 – volume: 49 start-page: 439 year: 2001 ident: 10.1016/j.biopsych.2011.04.013_bib44 article-title: Investigation of serum cytokine levels and cytokine production in whole blood cultures of paranoid schizophrenic patients publication-title: Arch Immunol. Ther Exp (Warsz) – volume: 63 start-page: 257 year: 2009 ident: 10.1016/j.biopsych.2011.04.013_bib16 article-title: Cytokines and schizophrenia: Microglia hypothesis of schizophrenia publication-title: Psychiatry Clin Neurosci doi: 10.1111/j.1440-1819.2009.01945.x – volume: 101 start-page: 36 year: 2009 ident: 10.1016/j.biopsych.2011.04.013_bib106 article-title: Compensatory anti-inflammatory response syndrome publication-title: Thromb Haemost doi: 10.1160/TH08-07-0421 – volume: 6 start-page: 61 year: 1995 ident: 10.1016/j.biopsych.2011.04.013_bib25 article-title: Changes in interleukin-1 beta and soluble interleukin-2 receptor levels in CSF and serum of schizophrenic patients publication-title: J Basic Clin Physiol Pharmacol doi: 10.1515/JBCPP.1995.6.1.61 – volume: 20 start-page: 269 year: 1996 ident: 10.1016/j.biopsych.2011.04.013_bib64 article-title: Elevated circulating levels of IL-6 in schizophrenia publication-title: Schizophr Res doi: 10.1016/0920-9964(96)00014-X – volume: 44 start-page: 165 year: 2000 ident: 10.1016/j.biopsych.2011.04.013_bib46 article-title: Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics publication-title: Schizophr Res doi: 10.1016/S0920-9964(99)00171-1 – volume: 64 start-page: 823 year: 2008 ident: 10.1016/j.biopsych.2011.04.013_bib1 article-title: General and specific cognitive deficits in schizophrenia: Goliath defeats David? publication-title: Biol Psychiatry doi: 10.1016/j.biopsych.2008.04.005 – volume: 248 start-page: 282 year: 1998 ident: 10.1016/j.biopsych.2011.04.013_bib81 article-title: Autoantibodies against 60-kDa heat shock protein in schizophrenia publication-title: Eur Arch Psychiatry Clin Neurosci doi: 10.1007/s004060050051 – volume: 26 start-page: 33 year: 2002 ident: 10.1016/j.biopsych.2011.04.013_bib29 article-title: Cytokine profiles in schizophrenic patients treated with risperidone: A 3-month follow-up study publication-title: Prog Neuropsychopharmacol Biol Psychiatry doi: 10.1016/S0278-5846(01)00221-4 – volume: 46 start-page: 291 year: 1989 ident: 10.1016/j.biopsych.2011.04.013_bib72 article-title: Elevated levels of soluble interleukin 2 receptors in schizophrenia publication-title: Arch Gen Psychiatry doi: 10.1001/archpsyc.1989.01810030097017 – volume: 46 start-page: 292 year: 1989 ident: 10.1016/j.biopsych.2011.04.013_bib38 article-title: Increased serum interleukin 2 receptor concentration in schizophrenic and brain-damaged subjects publication-title: Arch Gen Psychiatry doi: 10.1001/archpsyc.1989.01810030098018 – volume: 44 start-page: 321 year: 2010 ident: 10.1016/j.biopsych.2011.04.013_bib26 article-title: Cerebrospinal fluid analysis in affective and schizophrenic spectrum disorders: Identification of subgroups with immune responses and blood-CSF barrier dysfunction publication-title: J Psychiatr Res doi: 10.1016/j.jpsychires.2009.08.008 – volume: 159 start-page: 1029 year: 2002 ident: 10.1016/j.biopsych.2011.04.013_bib11 article-title: Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia publication-title: Am J Psychiatry doi: 10.1176/appi.ajp.159.6.1029 – volume: 84 start-page: 180 year: 2006 ident: 10.1016/j.biopsych.2011.04.013_bib8 article-title: An autoimmune or an inflammatory process in patients with schizophrenia, schizoaffective disorder, and in their biological relatives publication-title: Schizophr Res doi: 10.1016/j.schres.2006.02.003 – volume: 16 start-page: 10 year: 1967 ident: 10.1016/j.biopsych.2011.04.013_bib3 article-title: Schizophrenia as an immunologic disorder. II. Effects of serum protein fractions on brain function publication-title: Arch Gen Psychiatry doi: 10.1001/archpsyc.1967.01730190012002 – volume: 201 start-page: 383 year: 2008 ident: 10.1016/j.biopsych.2011.04.013_bib97 article-title: Lower serum cytokine levels in smokers than nonsmokers with chronic schizophrenia on long-term treatment with antipsychotics publication-title: Psychopharmacology (Berl) doi: 10.1007/s00213-008-1295-4 – volume: 29 start-page: 141 year: 1995 ident: 10.1016/j.biopsych.2011.04.013_bib56 article-title: Interleukin-2 and interleukin-6 in schizophrenia and mania: Effects of neuroleptics and mood stabilizers publication-title: J Psychiatr Res doi: 10.1016/0022-3956(94)00049-W – volume: 194 start-page: 434 year: 2009 ident: 10.1016/j.biopsych.2011.04.013_bib36 article-title: Metabolic profile of antipsychotic-naïve patients with nonaffective psychosis publication-title: Br J Psychiatry doi: 10.1192/bjp.bp.108.052605 – volume: 24 start-page: 449 year: 1994 ident: 10.1016/j.biopsych.2011.04.013_bib91 article-title: An association between anti-hippocampal antibody concentration and lymphocyte production of IL-2 in patients with schizophrenia publication-title: Psychol Med doi: 10.1017/S0033291700027410 – volume: 247 start-page: 308 year: 1997 ident: 10.1016/j.biopsych.2011.04.013_bib63 article-title: Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia publication-title: Eur Arch Psychiatry Clin Neurosci doi: 10.1007/BF02922260 – volume: 45 start-page: 135 year: 1995 ident: 10.1016/j.biopsych.2011.04.013_bib14 article-title: The macrophage-T-lymphocyte theory of schizophrenia: Additional evidence publication-title: Med Hypotheses doi: 10.1016/0306-9877(95)90062-4 – volume: 11 start-page: 726 year: 2009 ident: 10.1016/j.biopsych.2011.04.013_bib43 article-title: Similar immune profile in bipolar disorder and schizophrenia: Selective increase in soluble tumor necrosis factor receptor I and von Willebrand factor publication-title: Bipolar Disord doi: 10.1111/j.1399-5618.2009.00757.x – volume: 152 start-page: 1291 year: 1995 ident: 10.1016/j.biopsych.2011.04.013_bib78 article-title: Increases in CSF levels of interleukin-2 in schizophrenia: Effects of recurrence of psychosis and medication status publication-title: Am J Psychiatry doi: 10.1176/ajp.152.9.1291 – volume: 65 start-page: 940 year: 2004 ident: 10.1016/j.biopsych.2011.04.013_bib95 article-title: Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: Relationship to outcome in schizophrenia publication-title: J Clin Psychiatry doi: 10.4088/JCP.v65n0710 – volume: 87 start-page: 129 year: 1999 ident: 10.1016/j.biopsych.2011.04.013_bib7 article-title: Elevated interleukin-6 in schizophrenia publication-title: Psychiatry Res doi: 10.1016/S0165-1781(99)00053-0 – volume: 90 start-page: 179 year: 2007 ident: 10.1016/j.biopsych.2011.04.013_bib9 article-title: Celecoxib as adjunctive therapy in schizophrenia: A double-blind, randomized and placebo-controlled trial publication-title: Schizophr Res doi: 10.1016/j.schres.2006.11.016 – volume: 142 start-page: 313 year: 1996 ident: 10.1016/j.biopsych.2011.04.013_bib88 article-title: TGFbeta1 and TGFbeta2 concentrations are elevated in Parkinson's disease in ventricular cerebrospinal fluid publication-title: Exp Neurol doi: 10.1006/exnr.1996.0200 – volume: 16 start-page: 83 year: 1997 ident: 10.1016/j.biopsych.2011.04.013_bib89 article-title: Transforming growth factors beta 1 and beta 2 in the cerebrospinal fluid of chronic schizophrenic patients publication-title: Neuropsychopharmacology doi: 10.1016/S0893-133X(96)00143-1 – volume: 35 start-page: 767 year: 1994 ident: 10.1016/j.biopsych.2011.04.013_bib74 article-title: Increased serum soluble interleukin-2 receptors in Caucasian and Korean schizophrenic patients publication-title: Biol Psychiatry doi: 10.1016/0006-3223(94)91137-1 – volume: 71 start-page: 520 year: 2010 ident: 10.1016/j.biopsych.2011.04.013_bib10 article-title: Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: Results from a randomized, double-blind, placebo-controlled trial publication-title: J Clin Psychiatry doi: 10.4088/JCP.09m05117yel – volume: 37 start-page: 97 year: 1999 ident: 10.1016/j.biopsych.2011.04.013_bib23 article-title: Serum levels of soluble IL-2 receptor alpha, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration publication-title: Schizophr Res doi: 10.1016/S0920-9964(98)00140-6 – volume: 23 start-page: 887 year: 2009 ident: 10.1016/j.biopsych.2011.04.013_bib17 article-title: To assess, to control, to exclude: Effects of biobehavioral factors on circulating inflammatory markers publication-title: Brain Behav Immun doi: 10.1016/j.bbi.2009.04.005 – volume: 49 start-page: 661 year: 1991 ident: 10.1016/j.biopsych.2011.04.013_bib82 article-title: Serum interleukin-6 in schizophrenic patients publication-title: Life Sci doi: 10.1016/0024-3205(91)90112-O – volume: 37 start-page: S141 issue: suppl 2 year: 2004 ident: 10.1016/j.biopsych.2011.04.013_bib103 article-title: Mechanisms of relapse prevention in schizophrenia publication-title: Pharmacopsychiatry doi: 10.1055/s-2004-832668 – volume: 20 start-page: 199 year: 1996 ident: 10.1016/j.biopsych.2011.04.013_bib24 article-title: Serum cytokine concentrations in patients with schizophrenia publication-title: Schizophr Res doi: 10.1016/0920-9964(95)00089-5 – volume: 30 start-page: 314 year: 2002 ident: 10.1016/j.biopsych.2011.04.013_bib33 article-title: Serum interleukin 1 alpha and interleukin 2 levels in patients with schizophrenia publication-title: J Int Med Res doi: 10.1177/147323000203000313 – volume: 17 start-page: 383 year: 1993 ident: 10.1016/j.biopsych.2011.04.013_bib34 article-title: Interleukin-1 alpha and interleukin-2 in cerebrospinal fluid of schizophrenic subjects publication-title: Prog Neuropsychopharmacol Biol Psychiatry doi: 10.1016/0278-5846(93)90072-Z – volume: 50 start-page: 169 year: 2001 ident: 10.1016/j.biopsych.2011.04.013_bib19 article-title: Neuroleptics normalize increased release of interleukin-1 beta and tumor necrosis factor-alpha from monocytes in schizophrenia publication-title: Schizophr Res doi: 10.1016/S0920-9964(00)00156-0 – volume: 30 start-page: 1532 year: 2005 ident: 10.1016/j.biopsych.2011.04.013_bib96 article-title: Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: Association with psychopathology and response to antipsychotics publication-title: Neuropsychopharmacology doi: 10.1038/sj.npp.1300756 – volume: 51 start-page: 1 year: 1994 ident: 10.1016/j.biopsych.2011.04.013_bib39 article-title: Serum interleukin-6 concentration in schizophrenia: Elevation associated with duration of illness publication-title: Psychiatry Res doi: 10.1016/0165-1781(94)90042-6 – volume: 12 start-page: 294 year: 1997 ident: 10.1016/j.biopsych.2011.04.013_bib62 article-title: Soluble IL-6 receptors in the serum and cerebrospinal fluid of paranoid schizophrenic patients publication-title: Eur Psychiatry doi: 10.1016/S0924-9338(97)84789-X – volume: 142 start-page: 1184 year: 1985 ident: 10.1016/j.biopsych.2011.04.013_bib71 article-title: Serum interferon in patients with psychosis publication-title: Am J Psychiatry doi: 10.1176/ajp.142.10.1184 – volume: 28 start-page: 1515 year: 2003 ident: 10.1016/j.biopsych.2011.04.013_bib6 article-title: Elevated interleukin-6 in the cerebrospinal fluid of a previously delineated schizophrenia subtype publication-title: Neuropsychopharmacology doi: 10.1038/sj.npp.1300217 – volume: 102 start-page: 352 year: 2008 ident: 10.1016/j.biopsych.2011.04.013_bib32 article-title: Patients with schizophrenia show raised serum levels of the pro-inflammatory chemokine CCL2: Association with the metabolic syndrome in patients? publication-title: Schizophr Res doi: 10.1016/j.schres.2008.03.018 – volume: 106 start-page: 369 year: 2008 ident: 10.1016/j.biopsych.2011.04.013_bib90 article-title: Altered interleukin-3 serum levels in drug-naïve and neuroleptic-treated schizophrenic patients publication-title: Schizophr Res doi: 10.1016/j.schres.2008.09.001 – volume: 254 start-page: 14 year: 2004 ident: 10.1016/j.biopsych.2011.04.013_bib13 article-title: COX-2 inhibition as a treatment approach in schizophrenia: Immunological considerations and clinical effects of celecoxib add-on therapy publication-title: Eur Arch Psychiatry Clin Neurosci doi: 10.1007/s00406-004-0478-1 – volume: 23 start-page: 287 year: 2009 ident: 10.1016/j.biopsych.2011.04.013_bib22 article-title: Kynurenine pathway in psychosis: Evidence of increased tryptophan degradation publication-title: J Psychopharmacol doi: 10.1177/0269881108089583 – volume: 9 start-page: 661 year: 1996 ident: 10.1016/j.biopsych.2011.04.013_bib80 article-title: No evidence for autoimmunity in schizophrenia publication-title: J Autoimmun doi: 10.1006/jaut.1996.0086 – volume: 204 start-page: 177 year: 2009 ident: 10.1016/j.biopsych.2011.04.013_bib98 article-title: Superoxide dismutase and cytokines in chronic patients with schizophrenia: Association with psychopathology and response to antipsychotics publication-title: Psychopharmacology (Berl) doi: 10.1007/s00213-008-1447-6 – volume: 111 start-page: 11 year: 2001 ident: 10.1016/j.biopsych.2011.04.013_bib47 article-title: Effect of risperidone on serum cytokines publication-title: Int J Neurosci doi: 10.3109/00207450108986549 – volume: 15 start-page: 140 year: 2008 ident: 10.1016/j.biopsych.2011.04.013_bib30 article-title: Increased serum levels of inflammatory markers in chronic institutionalized patients with schizophrenia publication-title: Neuroimmunomodulation doi: 10.1159/000148197 – volume: 89 start-page: 346 year: 1994 ident: 10.1016/j.biopsych.2011.04.013_bib54 article-title: Immune-inflammatory markers in schizophrenia: Comparison to normal controls and effects of clozapine publication-title: Acta Psychiatr Scand doi: 10.1111/j.1600-0447.1994.tb01527.x – volume: 246 start-page: 279 year: 1996 ident: 10.1016/j.biopsych.2011.04.013_bib20 article-title: Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients publication-title: Eur Arch Psychiatry Clin Neurosci doi: 10.1007/BF02190280 – volume: 30 start-page: 20 year: 1994 ident: 10.1016/j.biopsych.2011.04.013_bib45 article-title: Plasma and cerebrospinal fluid interleukin-1 beta and interleukin-6 in hospitalized schizophrenic patients publication-title: Neuropsychobiology doi: 10.1159/000119130 – volume: 243 start-page: 7 year: 1993 ident: 10.1016/j.biopsych.2011.04.013_bib73 article-title: Increased serum soluble interleukin-2 receptors in schizophrenic monozygotic twins publication-title: Eur Arch Psychiatry Clin Neurosci doi: 10.1007/BF02191517 – volume: 150 start-page: 1408 year: 1993 ident: 10.1016/j.biopsych.2011.04.013_bib51 article-title: Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients publication-title: Am J Psychiatry doi: 10.1176/ajp.150.9.1408 – reference: 15291683 - J Clin Psychiatry. 2004 Jul;65(7):940-7 – reference: 18243335 - Psychiatry Res. 2008 Mar 15;158(2):206-16 – reference: 9690329 - Schizophr Res. 1998 Jun 22;32(1):9-15 – reference: 9928906 - Eur Arch Psychiatry Clin Neurosci. 1998;248(6):282-8 – reference: 12166349 - J Int Med Res. 2002 May-Jun;30(3):314-7 – reference: 8562579 - J Basic Clin Physiol Pharmacol. 1995;6(1):61-9 – reference: 9332905 - Eur Arch Psychiatry Clin Neurosci. 1997;247(4):228-33 – reference: 18838250 - Schizophr Res. 2008 Dec;106(2-3):369-70 – reference: 12042193 - Am J Psychiatry. 2002 Jun;159(6):1029-34 – reference: 12566931 - Neuropsychobiology. 2002;46(4):169-72 – reference: 8043705 - Biol Psychiatry. 1994 May 15;35(10):767-71 – reference: 8475320 - Prog Neuropsychopharmacol Biol Psychiatry. 1993 May;17(3):383-91 – reference: 8981392 - Neuropsychopharmacology. 1997 Jan;16(1):83-7 – reference: 4163018 - Arch Gen Psychiatry. 1967 Jan;16(1):10-23 – reference: 9477010 - Eur Arch Psychiatry Clin Neurosci. 1997;247(6):308-13 – reference: 17208413 - Schizophr Res. 2007 Feb;90(1-3):179-85 – reference: 4163019 - Arch Gen Psychiatry. 1967 Jan;16(1):1-9 – reference: 7653683 - Am J Psychiatry. 1995 Sep;152(9):1291-7 – reference: 20570110 - Schizophr Res. 2010 Aug;121(1-3):118-24 – reference: 19796773 - J Psychiatr Res. 2010 Apr;44(5):321-30 – reference: 10504009 - J Psychiatr Res. 1999 Sep-Oct;33(5):407-18 – reference: 7909714 - Br J Psychiatry. 1994 Feb;164(2):251-3 – reference: 15546066 - Pharmacopsychiatry. 2004 Nov;37 Suppl 2:S141-7 – reference: 1571315 - Schizophr Res. 1992 Mar;6(3):237-41 – reference: 1684719 - Schizophr Res. 1991 Oct;5(3):201-2 – reference: 19366488 - Int J Neuropsychopharmacol. 2009 Jul;12(6):861-5 – reference: 18719893 - Psychopharmacology (Berl). 2008 Dec;201(3):383-9 – reference: 17715203 - J Psychopharmacol. 2007 Nov;21(8):857-63 – reference: 10706993 - Eur Neuropsychopharmacol. 2000 Mar;10(2):119-24 – reference: 18472089 - Biol Psychiatry. 2008 Nov 1;64(9):823-7 – reference: 12223256 - Schizophr Res. 2002 Oct 1;57(2-3):247-58 – reference: 2784048 - Arch Gen Psychiatry. 1989 Mar;46(3):292 – reference: 12476326 - Mol Psychiatry. 2002;7(10):1107-14 – reference: 18562404 - J Psychopharmacol. 2009 May;23(3):287-94 – reference: 19698539 - Eur Psychiatry. 1997;12(6):294-9 – reference: 11339852 - Med Hypotheses. 2001 Apr;56(4):483-6 – reference: 10553735 - Am J Psychiatry. 1999 Nov;156(11):1725-9 – reference: 8102512 - Am J Psychiatry. 1993 Sep;150(9):1408-10 – reference: 7772617 - Eur Arch Psychiatry Clin Neurosci. 1995;244(6):325-9 – reference: 8827853 - Schizophr Res. 1996 Jul 5;20(3):269-73 – reference: 11814238 - Arch Immunol Ther Exp (Warsz). 2001;49(6):439-45 – reference: 16530388 - Schizophr Res. 2006 May;84(1):180-2 – reference: 8546160 - Am J Med Genet. 1995 Oct 9;60(5):448-51 – reference: 21255481 - Int J Neuropsychopharmacol. 2011 Jul;14(6):746-55 – reference: 2798648 - Psychol Med Monogr Suppl. 1989;15:1-46 – reference: 15840416 - Psychiatry Res. 2005 Apr 15;134(2):151-9 – reference: 14662550 - Arch Gen Psychiatry. 2003 Dec;60(12):1187-92 – reference: 19058794 - Biol Psychiatry. 2009 Mar 15;65(6):481-8 – reference: 9323355 - Schizophr Res. 1997 Aug 29;26(2-3):227-33 – reference: 19389469 - Brain Behav Immun. 2009 Oct;23(7):887-97 – reference: 8863007 - Eur Arch Psychiatry Clin Neurosci. 1996;246(5):279-84 – reference: 1697774 - Br J Psychiatry. 1990 Jul;157:136-8 – reference: 11913333 - Int J Neurosci. 2001;111(1-2):11-9 – reference: 9278953 - Prog Neuropsychopharmacol Biol Psychiatry. 1997 Jul;21(5):817-27 – reference: 14623497 - Prostaglandins Leukot Essent Fatty Acids. 2003 Dec;69(6):429-36 – reference: 19939410 - J Psychiatr Res. 2010 May;44(7):441-6 – reference: 8933282 - J Autoimmun. 1996 Oct;9(5):661-6 – reference: 11853116 - Prog Neuropsychopharmacol Biol Psychiatry. 2002 Jan;26(1):33-9 – reference: 10227112 - Schizophr Res. 1999 May 4;37(1):97-106 – reference: 10962218 - Schizophr Res. 2000 Sep 1;44(3):165-75 – reference: 11950553 - Schizophr Res. 2002 Apr 1;54(3):281-91 – reference: 2784047 - Arch Gen Psychiatry. 1989 Mar;46(3):291-2 – reference: 10579546 - Psychiatry Res. 1999 Oct 11;87(2-3):129-36 – reference: 8531836 - Med Hypotheses. 1995 Aug;45(2):135-41 – reference: 8998275 - Schizophr Res. 1996 Jul;21(1):39-50 – reference: 8445045 - J Clin Immunol. 1993 Jan;13(1):58-67 – reference: 1865759 - Life Sci. 1991;49(9):661-4 – reference: 16504930 - Int Immunopharmacol. 2006 Apr;6(4):666-71 – reference: 19920835 - Mol Psychiatry. 2009 Dec;14(12):1069-71 – reference: 15610925 - Prog Neuropsychopharmacol Biol Psychiatry. 2004 Nov;28(7):1129-34 – reference: 11163541 - Schizophr Res. 2001 Jan 15;47(1):13-25 – reference: 19132187 - Thromb Haemost. 2009 Jan;101(1):36-47 – reference: 11439237 - Schizophr Res. 2001 Jul 1;50(3):169-75 – reference: 19407273 - Br J Psychiatry. 2009 May;194(5):434-8 – reference: 19735687 - Hum Immunol. 2010 Jan;71(1):50-7 – reference: 18679053 - Neuroimmunomodulation. 2008;15(2):140-4 – reference: 9187011 - Schizophr Res. 1997 May 24;25(2):123-9 – reference: 19502081 - Cytokine. 2009 Jul;47(1):1-5 – reference: 18486454 - Schizophr Res. 2008 Jul;102(1-3):352-5 – reference: 11545247 - Mediators Inflamm. 2001 Jun;10(3):109-15 – reference: 19139851 - Psychopharmacology (Berl). 2009 May;204(1):177-84 – reference: 19390223 - Neuropsychobiology. 2009;59(2):123-9 – reference: 8794510 - Schizophr Res. 1996 May;20(1-2):199-203 – reference: 15886721 - Neuropsychopharmacology. 2005 Aug;30(8):1532-8 – reference: 18722671 - Psychiatry Res. 2008 Sep 30;160(3):256-62 – reference: 9247977 - Psychiatry Res. 1997 Jun 16;71(1):11-7 – reference: 2412455 - Am J Psychiatry. 1985 Oct;142(10):1184-6 – reference: 8084939 - Psychol Med. 1994 May;24(2):449-55 – reference: 4163107 - Arch Gen Psychiatry. 1967 Jan;16(1):24-33 – reference: 7666381 - J Psychiatr Res. 1995 Mar-Apr;29(2):141-52 – reference: 18005941 - Biol Psychiatry. 2008 Apr 15;63(8):801-8 – reference: 14991374 - Eur Arch Psychiatry Clin Neurosci. 2004 Feb;254(1):14-22 – reference: 8067274 - Acta Psychiatr Scand. 1994 May;89(5):346-51 – reference: 7910974 - Psychiatry Res. 1994 Jan;51(1):1-10 – reference: 20492850 - J Clin Psychiatry. 2010 May;71(5):520-7 – reference: 7969854 - Neuropsychobiology. 1994;30(1):20-3 – reference: 19839997 - Bipolar Disord. 2009 Nov;11(7):726-34 – reference: 9323354 - Schizophr Res. 1997 Aug 29;26(2-3):221-5 – reference: 7872033 - Acta Psychiatr Scand. 1994 Nov;90(5):311-5 – reference: 8934562 - Exp Neurol. 1996 Dec;142(2):313-22 – reference: 12799618 - Neuropsychopharmacology. 2003 Aug;28(8):1515-20 – reference: 8399412 - Eur Arch Psychiatry Clin Neurosci. 1993;243(1):7-10 – reference: 19579286 - Psychiatry Clin Neurosci. 2009 Jun;63(3):257-65 |
| SSID | ssj0007221 |
| Score | 2.5980866 |
| SecondaryResourceType | review_article |
| Snippet | Schizophrenia is associated with immune system dysfunction, including aberrant cytokine levels. We performed a meta-analysis of these associations, considering... Background Schizophrenia is associated with immune system dysfunction, including aberrant cytokine levels. We performed a meta-analysis of these associations,... |
| SourceID | pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 663 |
| SubjectTerms | Antipsychotic Agents - pharmacology Antipsychotic Agents - therapeutic use Biomarkers - blood Biomarkers - cerebrospinal fluid Cytokines Cytokines - blood Cytokines - cerebrospinal fluid Cytokines - drug effects first-episode psychosis Humans Interleukin 1 Receptor Antagonist Protein - blood Interleukin 1 Receptor Antagonist Protein - cerebrospinal fluid Interleukin 1 Receptor Antagonist Protein - drug effects meta-analysis Psychiatry Receptors, Cytokine - blood Receptors, Cytokine - drug effects Recurrence relapse schizophrenia Schizophrenia - blood Schizophrenia - cerebrospinal fluid Schizophrenia - diagnosis Schizophrenia - drug therapy |
| Title | Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0006322311004045 https://www.clinicalkey.es/playcontent/1-s2.0-S0006322311004045 https://dx.doi.org/10.1016/j.biopsych.2011.04.013 https://www.ncbi.nlm.nih.gov/pubmed/21641581 https://www.proquest.com/docview/892947188 https://pubmed.ncbi.nlm.nih.gov/PMC4071300 |
| Volume | 70 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV07b9swECaCFH0sReq-3DzAoatskqJe3QyjgdPCWdoA2QiSIlElhhRU8pClv71HiXTsBkWKZhV5EMG7430E775D6CNTJSkkOFJqcxPxpGCRyi2JstSoLOaxJn1t1fI8XVzwL5fJ5R6ah1oYl1bpz_7hTO9Pa_9l6ndzelNVrsYXwitEt570DJCJq2DnmUvrm_y6S_PIGPNd89LIzd6qEr6aqKrpk4o9lSefEBr_LUDdB6B_5lFuBabTA_TSI0o8Gxb9Cu2ZeoSeDj0mb0fo-Ty0dBuhZ0v_kv4ayaXpZBQoSXBj8fy2a65hDM9WPdOys0dc1fjbdlreJ-yJRFfYwdR1i2Vd4lndVb6cq9J4IERu36CL08_f54vIt1uIdMrTLrKaM5pKoxPJwS1LUjJrJdyQGY-tItTmxNDMsEwBKLAysUZyrpTOC605lTR-i_brpjbvEdY0USYrCypZyUsFhlKmMWAdlsQG7kz5GCVhj4X2XOSuJcZKhKSzKxF0I5xuBOECdDNG043czcDG8aBEFlQoQq0pnI4CAsb_SZrWO3krqGiZIOKeIY5RsZHcseV_-isOdibAONzrjaxNs25FDkDWIQnYvHeD2W22ANQGOCynsOQdg9xMcBziuyN19aPnEnf3-ZiQD49Y8iF6wUJiJD1C-93PtTkGpNapk94VT9CT2dnXxflvF3pAOg |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3Nb9MwFLdGJxgXBOWrfPrANavtOF_cqoqpY2svbNJulu3YWkaVTCQ97L_nObGrlgmB4BrnKZbf18_Ke7-H0CemSlJIcKTU5ibiScEilVsSZalRWcxjTfrequUqXVzyr1fJ1QGah14YV1bpY_8Q0_to7Z9M_WlOb6vK9fhCeoXs1pOeATJ5gA4dOxUfocPZ6dlitQ3IGWN-cF4aOYGdRuGbY1U1fV2xZ_Pkx4TGv8tR9zHor6WUO7np5Cl64kElng37foYOTD1GD4cxk3djdDQPU93G6NHS_0x_juTSdDIKrCS4sXh-1zXfYQ3P1j3ZsjNJXNX4225l3mfsuUTX2CHVTYtlXeJZ3VW-o6vSeOBEbl-gy5MvF_NF5CcuRDrlaRdZzRlNpdGJ5OCZJSmZtRIuyYzHVhFqc2JoZlimABdYmVgjOVdK54XWnEoav0SjuqnNa4Q1TZTJyoJKVvJSga2UaQxwhyWxgWtTPkFJOGOhPR25m4qxFqHu7EYE3QinG0G4AN1M0HQrdzsQcvxRIgsqFKHdFAKkgJzxb5Km9X7eCipaJoi4Z4sTVGwl98z5r76Kg50JMA73A0fWptm0Igcs68AEHN6rwey2RwBqAyiWU9jynkFuX3A04vsrdXXd04m7K31MyJv_2PJHdLS4WJ6L89PV2Vv0mIU6SfoOjbofG_MegFunPnjH_AnmLULr |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Meta-Analysis+of+Cytokine+Alterations+in+Schizophrenia%3A+Clinical+Status+and+Antipsychotic+Effects&rft.jtitle=Biological+psychiatry+%281969%29&rft.au=Miller%2C+Brian+J.&rft.au=Buckley%2C+Peter&rft.au=Seabolt%2C+Wesley&rft.au=Mellor%2C+Andrew&rft.date=2011-10-01&rft.issn=0006-3223&rft.eissn=1873-2402&rft.volume=70&rft.issue=7&rft.spage=663&rft.epage=671&rft_id=info:doi/10.1016%2Fj.biopsych.2011.04.013&rft_id=info%3Apmid%2F21641581&rft.externalDocID=PMC4071300 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F00063223%2FS0006322311X00173%2Fcov150h.gif |